BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. [PMID: 19095497 DOI: 10.1016/s1470-2045(08)70285-7] [Cited by in Crossref: 3367] [Cited by in F6Publishing: 1796] [Article Influence: 259.0] [Reference Citation Analysis]
Number Citing Articles
1 Chopra S, George K, Engineer R, Rajamanickam K, Nojin S, Joshi K, Swamidas J, Shetty N, Patkar S, Patil P, Ostwal V, Mehta S, Goel M. Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. Br J Radiol 2019;92:20181053. [PMID: 31219706 DOI: 10.1259/bjr.20181053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med. 2016;6:21-36. [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 63] [Article Influence: 14.6] [Reference Citation Analysis]
3 Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells. Onco Targets Ther 2020;13:9721-30. [PMID: 33061451 DOI: 10.2147/OTT.S262089] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
4 Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF. Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clin Cancer Res 2017;23:4633-41. [PMID: 28465443 DOI: 10.1158/1078-0432.CCR-16-3171] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 10.8] [Reference Citation Analysis]
5 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol. 2013;19:7316-7326. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
6 Zheng J, Shao G, Luo J. Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib. Clin Transl Oncol. 2014;16:1012-1017. [PMID: 24894839 DOI: 10.1007/s12094-014-1189-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Kang MK, Park JG, Lee HJ. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore). 2018;97:e0611. [PMID: 29703062 DOI: 10.1097/md.0000000000010611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol. 2011;4:30. [PMID: 21729319 DOI: 10.1186/1756-8722-4-8730] [Reference Citation Analysis]
9 Zhu Q, Zhang X, Li J, Huang L, Yan J, Xu F, Yan Y. Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapy. Ann Transl Med 2015;3:285. [PMID: 26697445 DOI: 10.3978/j.issn.2305-5839.2015.10.24] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N, An X, Yu J, Li H, Ren X. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34:194-203. [PMID: 24337625 DOI: 10.1007/s10875-013-9976-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 6.5] [Reference Citation Analysis]
11 Ferrín G, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M. Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. Hepat Med 2015;7:1-10. [PMID: 25926760 DOI: 10.2147/HMER.S50161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
12 You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. J Hematol Oncol 2016;9:20. [PMID: 26957312 DOI: 10.1186/s13045-016-0253-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
13 Yutani S, Shirahama T, Muroya D, Matsueda S, Yamaguchi R, Morita M, Shichijo S, Yamada A, Sasada T, Itoh K. Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. Cancer Sci. 2017;108:1732-1738. [PMID: 28622427 DOI: 10.1111/cas.13301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
14 Qi X, Guo X. Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies. Prz Gastroenterol. 2015;10:142-147. [PMID: 26516379 DOI: 10.5114/pg.2015.52470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Wang QS, Shi LL, Sun F, Zhang YF, Chen RW, Yang SL, Hu JL. High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma. Dis Markers 2019;2019:9267046. [PMID: 30881525 DOI: 10.1155/2019/9267046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
16 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 Amaro CP, Tam VC. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond. Curr Oncol 2020;27:S173-80. [PMID: 33343211 DOI: 10.3747/co.27.7103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 López-Grueso MJ, González R, Muntané J, Bárcena JA, Padilla CA. Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells. Antioxidants (Basel) 2019;8:E501. [PMID: 31652503 DOI: 10.3390/antiox8100501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199.] [Reference Citation Analysis]
20 Shin IS, Rim CH. Stepwise-Hierarchical Pooled Analysis for Synergistic Interpretation of Meta-analyses Involving Randomized and Observational Studies: Methodology Development. J Med Internet Res 2021;23:e29642. [PMID: 34315697 DOI: 10.2196/29642] [Reference Citation Analysis]
21 Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y, Wang F, Duan X, Li J, Zhang W, Wang H. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. EBioMedicine 2017;22:58-67. [PMID: 28754304 DOI: 10.1016/j.ebiom.2017.07.014] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
22 Liu Z, Li X, He X, Xu Y, Wang X. Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report. BMC Cancer. 2019;19:1062. [PMID: 31703571 DOI: 10.1186/s12885-019-6287-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget. 2017;8:41242-41255. [PMID: 28465485 DOI: 10.18632/oncotarget.17168] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
24 Zhang XH, Cao MQ, Li XX, Zhang T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J Hepatol 2020;12:766-74. [PMID: 33200015 DOI: 10.4254/wjh.v12.i10.766] [Reference Citation Analysis]
25 Blumer T, Fofana I, Matter MS, Wang X, Montazeri H, Calabrese D, Coto-Llerena M, Boldanova T, Nuciforo S, Kancherla V, Tornillo L, Piscuoglio S, Wieland S, Terracciano LM, Ng CKY, Heim MH. Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. Hepatol Commun 2019;3:971-86. [PMID: 31334445 DOI: 10.1002/hep4.1365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
26 Lee DW, Jang MJ, Lee KH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. Br J Cancer 2016;115:1201-5. [PMID: 27736843 DOI: 10.1038/bjc.2016.322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
27 Sprinzl MF, Kirstein MM, Koch S, Seib ML, Weinmann-Menke J, Lang H, Düber C, Toenges G, Zöller D, Marquardt JU, Wörns MA, Galle PR, Vogel A, Pinter M, Weinmann A. Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. Liver Cancer 2019;8:387-402. [PMID: 31768347 DOI: 10.1159/000492628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
28 Chow AK, Yau SW, Ng L. Novel molecular targets in hepatocellular carcinoma. World J Clin Oncol 2020;11:589-605. [PMID: 32879846 DOI: 10.5306/wjco.v11.i8.589] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhong D, Cen H. Aberrant promoter methylation profiles and association with survival in patients with hepatocellular carcinoma. Onco Targets Ther 2017;10:2501-9. [PMID: 28507442 DOI: 10.2147/OTT.S128058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
30 Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate. Int J Oncol 2016;48:1794-804. [PMID: 26936487 DOI: 10.3892/ijo.2016.3403] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
31 Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. Br J Pharmacol 2013;168:658-72. [PMID: 22978563 DOI: 10.1111/j.1476-5381.2012.02212.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
32 Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers (Basel) 2020;12:E1116. [PMID: 32365655 DOI: 10.3390/cancers12051116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
33 Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:187204. [PMID: 23533994 DOI: 10.1155/2013/187204] [Cited by in Crossref: 209] [Cited by in F6Publishing: 192] [Article Influence: 23.2] [Reference Citation Analysis]
34 Ha Y, Mohamed Ali MA, Petersen MM, Harmsen WS, Therneau TM, Lee HC, Ryoo BY, Bampoh S, Valles KA, Mady M, Missula VR, Prasai K, Roberts LR, Kim KM. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. Hepatol Int 2020;14:776-87. [PMID: 32740886 DOI: 10.1007/s12072-020-10076-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
35 Zhang X, Yang H, Yue S, He G, Qu S, Zhang Z, Ma B, Ding R, Peng W, Zhang H, Yang Z, Dou K, Tao K, Li X. The mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinoma. Cancer Med 2017;6:1941-51. [PMID: 28675698 DOI: 10.1002/cam4.1127] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
36 Stewart DJ, Kurzrock R. Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer 2013;13:193. [PMID: 23587187 DOI: 10.1186/1471-2407-13-193] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
37 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Reference Citation Analysis]
38 Tsuchiya K, Kurosaki M, Sakamoto A, Marusawa H, Kojima Y, Hasebe C, Arai H, Joko K, Kondo M, Tsuji K, Sohda T, Kimura H, Ogawa C, Uchida Y, Wada S, Kobashi H, Furuta K, Shigeno M, Kusakabe A, Akahane T, Narita R, Yoshida H, Mitsuda A, Ide Y, Matsushita T, Izumi N, On Behalf Of Japanese Red Cross Liver Study Group. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers (Basel) 2021;13:2608. [PMID: 34073396 DOI: 10.3390/cancers13112608] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Shek D, Read SA, Nagrial A, Carlino MS, Gao B, George J, Ahlenstiel G. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist 2021;26:e1216-25. [PMID: 33818870 DOI: 10.1002/onco.13776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178-184. [PMID: 25965437 DOI: 10.1155/2015/824263] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
41 Xie H, Yu H, Tian S, Yang X, Wang X, Yang Z, Wang H, Guo Z. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis. Oncotarget 2017;8:100508-23. [PMID: 29245997 DOI: 10.18632/oncotarget.20119] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
42 Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020;10:297-306. [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297] [Reference Citation Analysis]
43 Du J, Mao Y, Liu M, Tie Y, Huang H, Zhao J, Xiang Z, Luo D. Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:102413-9. [PMID: 29254256 DOI: 10.18632/oncotarget.22061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 2015;35:751-9. [PMID: 26446004 DOI: 10.1007/s40261-015-0333-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
45 Zhu YJ, Zheng B, Wang HY, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614-622. [PMID: 28344323 DOI: 10.1038/aps.2017.5] [Cited by in Crossref: 209] [Cited by in F6Publishing: 201] [Article Influence: 52.3] [Reference Citation Analysis]
46 Gao F, Huang C, Zhang Y, Sun R, Zhang Y, Wang H, Zhang S. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa. Cancer Biol Ther 2016;17:595-8. [PMID: 27030639 DOI: 10.1080/15384047.2016.1167290] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
47 Bhatia R, Ravulapati S, Befeler A, Dombrowski J, Gadani S, Poddar N. Hepatocellular Carcinoma with Bone Metastases: Incidence, Prognostic Significance, and Management-Single-Center Experience. J Gastrointest Cancer 2017;48:321-5. [PMID: 28891006 DOI: 10.1007/s12029-017-9998-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
48 Kimura Y, Kaneko R, Yano Y, Kamada K, Ikehara T, Nagai H, Sato Y, Igarashi Y. The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE. Asian Pac J Cancer Prev 2020;21:1797-805. [PMID: 32592380 DOI: 10.31557/APJCP.2020.21.6.1797] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Higgins MC, Soulen MC. Combining locoregional therapies in the treatment of hepatocellular carcinoma. Semin Intervent Radiol. 2013;30:74-81. [PMID: 24436520 DOI: 10.1055/s-0033-1333656] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
50 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 671] [Article Influence: 62.2] [Reference Citation Analysis]
51 Kikuchi L, Oliveira CP, Alvares-da-Silva MR, Tani CM, Diniz MA, Stefano JT, Chagas AL, Alencar RS, Vezozzo DC, Santos GR, Campos PB, Alves VA, Ratziu V, Carrilho FJ. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. Am J Clin Oncol. 2016;39:428-432. [PMID: 25268068 DOI: 10.1097/coc.0000000000000134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
52 Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol 2021;13:17588359211031141. [PMID: 34377156 DOI: 10.1177/17588359211031141] [Reference Citation Analysis]
53 Carr BI. Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. Hepatoma Res 2019;5:3. [PMID: 30842979 DOI: 10.20517/2394-5079.2018.113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kissel M, Berndt S, Fiebig L, Kling S, Ji Q, Gu Q, Lang T, Hafner FT, Teufel M, Zopf D. Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Oncotarget 2017;8:107096-108. [PMID: 29291014 DOI: 10.18632/oncotarget.22334] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
55 Ravaioli M, Cucchetti A, Pinna AD, De Pace V, Neri F, Barbera MA, Maroni L, Frega G, Palloni A, De Lorenzo S, Ripoli MC, Pantaleo MA, Cescon M, Del Gaudio M, Brandi G. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. Sci Rep 2017;7:11305. [PMID: 28900245 DOI: 10.1038/s41598-017-11810-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
56 Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLoS One 2013;8:e83627. [PMID: 24391798 DOI: 10.1371/journal.pone.0083627] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
57 Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraya H, Lacornerie T, Lartigau E, Mirabel X. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One. 2013;8:e77472. [PMID: 24147002 DOI: 10.1371/journal.pone.0077472] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 9.5] [Reference Citation Analysis]
58 Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15:285-292. [PMID: 20203173 DOI: 10.1634/theoncologist.2009-0316] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
59 Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology 2019;8:1615817. [PMID: 31413923 DOI: 10.1080/2162402X.2019.1615817] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 15.5] [Reference Citation Analysis]
60 Furtado LV, Segal JP. Circulating Tumor DNA Testing for Liver Cancer. Cell Mol Gastroenterol Hepatol 2015;1:458-9. [PMID: 28210695 DOI: 10.1016/j.jcmgh.2015.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
61 Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015;7:2053-7. [PMID: 26301047 DOI: 10.4254/wjh.v7.i17.2053] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
62 Huang F, Wang BR, Wang YG. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. World J Gastroenterol. 2018;24:4643-4651. [PMID: 30416312 DOI: 10.3748/wjg.v24.i41.4643] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 61] [Article Influence: 31.5] [Reference Citation Analysis]
63 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 15.0] [Reference Citation Analysis]
64 Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-8. [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
65 Zhuang PY, Zhang KW, Wang JD, Zhou XP, Liu YB, Quan ZW, Shen J. Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells. Oncotarget 2017;8:77915-27. [PMID: 29100435 DOI: 10.18632/oncotarget.20946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
66 Wang L, Ke J, Wang C, Li Y, Wu G, Ding Q, Luo Q, Cai R, Lv P, Song T, Xiong S. Efficacy and Safety of Banxia XieXin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients With Advanced Hepatocellular Carcinoma. Integr Cancer Ther 2020;19:1534735420942587. [PMID: 32787468 DOI: 10.1177/1534735420942587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Zahavi T, Lanton T, Divon MS, Salmon A, Peretz T, Galun E, Axelrod JH, Sonnenblick A. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. Oncotarget 2016;7:4860-70. [PMID: 26695439 DOI: 10.18632/oncotarget.6638] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
68 Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N. Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clin Mol Hepatol. 2020;26:155-162. [PMID: 31937081 DOI: 10.3350/cmh.2019.0021n] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
69 Zhu N, Weng S, Wang J, Chen J, Yu L, Fang X, Yuan Y. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. J Cancer Res Clin Oncol 2019;145:3021-36. [PMID: 31617075 DOI: 10.1007/s00432-019-03044-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
70 Yoon EL, Yeon JE, Ko E, Lee HJ, Je JH, Yoo YJ, Kang SH, Suh SJ, Kim JH, Seo YS. An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. J Korean Med Sci. 2017;32:212-220. [PMID: 28049231 DOI: 10.3346/jkms.2017.32.2.212] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
71 Nakamura K, Beppu T, Hayashi H, Okabe H, Imai K, Nitta H, Chikamoto A, Ishiko T, Sasaki M, Baba H. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection. Int Surg. 2015;100:908-914. [PMID: 26011214 DOI: 10.9738/intsurg-d-14-00133.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
72 Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301. [PMID: 21386818 DOI: 10.1038/nrclinonc.2011.30] [Cited by in Crossref: 293] [Cited by in F6Publishing: 284] [Article Influence: 29.3] [Reference Citation Analysis]
73 Aishanjiang K, Wei XD, Fu Y, Lin X, Ma Y, Le J, Han Q, Wang X, Kong X, Gu J, Wu H. Circular RNAs and Hepatocellular Carcinoma: New Epigenetic Players With Diagnostic and Prognostic Roles. Front Oncol 2021;11:653717. [PMID: 33959506 DOI: 10.3389/fonc.2021.653717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
74 Connell LC, Harding JJ, Abou-Alfa GK. Advanced Hepatocellular Cancer: the Current State of Future Research. Curr Treat Options Oncol. 2016;17:43. [PMID: 27344158 DOI: 10.1007/s11864-016-0415-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
75 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
76 Lim C, Compagnon P, Sebagh M, Salloum C, Calderaro J, Luciani A, Pascal G, Laurent A, Levesque E, Maggi U, Feray C, Cherqui D, Castaing D, Azoulay D. Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery. HPB (Oxford). 2015;17:611-623. [PMID: 25980326 DOI: 10.1111/hpb.12416] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
77 Peveling-Oberhag J, Seiz A, Döring C, Hartmann S, Köberle V, Liese J, Zeuzem S, Hansmann ML, Piiper A. MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Transl Oncol 2014;7:672-80. [PMID: 25500075 DOI: 10.1016/j.tranon.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
78 Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC, Sun X, Song WM, Koh A, Canasto-Chibuque C. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 2016;36:108-118. [PMID: 26058462 DOI: 10.1111/liv.12889] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
79 Rigalli JP, Ciriaci N, Arias A, Ceballos MP, Villanueva SS, Luquita MG, Mottino AD, Ghanem CI, Catania VA, Ruiz ML. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS One 2015;10:e0119502. [PMID: 25781341 DOI: 10.1371/journal.pone.0119502] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
80 Zhong JH. The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma. Tumour Biol. 2015;36:8271-8272. [PMID: 26499777 DOI: 10.1007/s13277-015-4279-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
81 Yoo JJ, Yu SJ, Na J, Kim K, Cho YY, Lee YB, Cho EJ, Lee JH, Kim YJ, Youn H, Yoon JH. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E1292. [PMID: 30875800 DOI: 10.3390/ijms20061292] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
82 Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol. 2012;30:3361-3367. [PMID: 22915658 DOI: 10.1200/jco.2011.41.2395] [Cited by in Crossref: 127] [Cited by in F6Publishing: 69] [Article Influence: 14.1] [Reference Citation Analysis]
83 Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21:10327-10335. [PMID: 26420959 DOI: 10.3748/wjg.v21.i36.10327] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
84 Iavarone M, Primignani M, Vavassori S, Sangiovanni A, La Mura V, Romeo R, Colombo M. Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterol J 2016;4:363-70. [PMID: 27403302 DOI: 10.1177/2050640615615041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
85 Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18:44. [PMID: 29568237 DOI: 10.1186/s12935-018-0538-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 25.3] [Reference Citation Analysis]
86 Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2019;25:80-9. [PMID: 30190369 DOI: 10.1158/1078-0432.CCR-18-0847] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
87 Singh AK, Kumar R, Pandey AK. Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers. Curr Chem Genom Transl Med. 2018;12:9-26. [PMID: 30069430 DOI: 10.2174/2213988501812010009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 17.3] [Reference Citation Analysis]
88 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Kim JS, Choi GH, Jung Y, Kim KM, Jang SJ, Yu ES, Lee HC. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. J Cancer Res Clin Oncol 2018;144:1487-501. [PMID: 29858683 DOI: 10.1007/s00432-018-2672-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
90 Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep 2017;7:44123. [PMID: 28276530 DOI: 10.1038/srep44123] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
91 Kennedy AS, Sangro B. Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep. 2014;16:373. [PMID: 24488546 DOI: 10.1007/s11912-013-0373-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
92 Augello G, Puleio R, Emma MR, Cusimano A, Loria GR, McCubrey JA, Montalto G, Cervello M. A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle. 2016;15:573-583. [PMID: 26794644 DOI: 10.1080/15384101.2016.1138183] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
93 Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011;21:35-43. [PMID: 20946957 DOI: 10.1016/j.semcancer.2010.10.007] [Cited by in Crossref: 216] [Cited by in F6Publishing: 196] [Article Influence: 19.6] [Reference Citation Analysis]
94 Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, Li X, Ren T, Yang R, Feng F, Li BA, Zhao Q. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis 2018;9:743. [PMID: 29970890 DOI: 10.1038/s41419-018-0804-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 54] [Article Influence: 14.0] [Reference Citation Analysis]
95 Li X, Zhang D, Guan S, Ye W, Liu L, Lou L. Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget 2017;8:93179-85. [PMID: 29190987 DOI: 10.18632/oncotarget.21452] [Reference Citation Analysis]
96 Yu WC, Zhang KZ, Chen SG, Liu WF. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study. Medicine (Baltimore). 2018;97:e9704. [PMID: 29505026 DOI: 10.1097/md.0000000000009704] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
97 Feliu J, Sastre J, Maurel J, Isla D. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. Clin Transl Oncol 2011;13:536-44. [PMID: 21821487 DOI: 10.1007/s12094-011-0694-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
98 Nguyen TTH, Nguyen VH, Nguyen VH, Nguyen TL, Le VQ. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam. Cancer Control. 2019;26:1073274819865269. [PMID: 31364390 DOI: 10.1177/1073274819865269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
99 Xia YQ, Hua RJ, Juan C, Zhong ZH, Tao CS, Fang R, Lin H, Rui G, Yong C. SIRT6 Depletion Sensitizes Human Hepatoma Cells to Chemotherapeutics by Downregulating MDR1 Expression. Front Pharmacol 2018;9:194. [PMID: 29563873 DOI: 10.3389/fphar.2018.00194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
100 Shao YY, Lu LC, Cheng AL, Hsu CH. Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. Oncologist 2011;16:82-6. [PMID: 21212425 DOI: 10.1634/theoncologist.2010-0272] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
101 Ikuta S, Aihara T, Yamanaka N. Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: a retrospective single-institution study. Contemp Oncol (Pozn) 2018;22:165-71. [PMID: 30455588 DOI: 10.5114/wo.2018.78948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 156] [Article Influence: 33.4] [Reference Citation Analysis]
103 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
104 Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2012;118:2424-2430. [PMID: 21953248 DOI: 10.1002/cncr.26556] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
105 Sieghart W, Pinter M, Reisegger M, Müller C, Ba-Ssalamah A, Lammer J, Peck-Radosavljevic M. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. Eur Radiol. 2012;22:1214-1223. [PMID: 22215073 DOI: 10.1007/s00330-011-2368-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
106 Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013;19:1557-1566. [PMID: 23362324 DOI: 10.1158/1078-0432.ccr-12-3041] [Cited by in Crossref: 50] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
107 Chen YY, Yen HH, Chou KC, Wu SS. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis. World J Gastroenterol 2012;18:466-71. [PMID: 22346253 DOI: 10.3748/wjg.v18.i5.466] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
108 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Rep 2020;2:100100. [PMID: 32514496 DOI: 10.1016/j.jhepr.2020.100100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
109 Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver. 2013;7:696-703. [PMID: 24312711 DOI: 10.5009/gnl.2013.7.6.696] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
110 Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, Tanaka T, Endo M, Itoh Y. Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer 2017;6:275-86. [PMID: 29234631 DOI: 10.1159/000473887] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
111 Fan Y, Li S, Ding X, Yue J, Jiang J, Zhao H, Hao R, Qiu W, Liu K, Li Y, Wang S, Zheng L, Ye B, Meng K, Xu B. First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. BMC Cancer 2019;19:279. [PMID: 30922248 DOI: 10.1186/s12885-019-5471-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
112 Feng YH, Tung CL, Su YC, Tsao CJ, Wu TF. Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib. Cancer Genomics Proteomics 2019;16:569-76. [PMID: 31659110 DOI: 10.21873/cgp.20159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
113 Aihara A, Huang CK, Olsen MJ, Lin Q, Chung W, Tang Q, Dong X, Wands JR. A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60:1302-1313. [PMID: 24954865 DOI: 10.1002/hep.27275] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
114 Kuczynski EA, Kerbel RS. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. Chin J Cancer 2016;35:97. [PMID: 27887628 DOI: 10.1186/s40880-016-0162-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
115 Lee HW, Kim HS, Kim SU, Kim DY, Kim BK, Park JY, Ahn SH, Jeon MY, Heo JY, Park SY, Lee YR, Jang SK, Lee SH, Jang SY, Tak WY, Han KH. Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. Gut Liver 2017;11:693-701. [PMID: 28651299 DOI: 10.5009/gnl16391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
116 Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Furuta M, Tsunoda T, Miyano S, Kubo M, Aikata H, Ochi H, Kawakami YI, Arihiro K, Ohdan H, Nakagawa H, Chayama K. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol Gastroenterol Hepatol. 2015;1:516-534. [PMID: 28210698 DOI: 10.1016/j.jcmgh.2015.06.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
117 Kaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. J Vasc Interv Radiol. 2018;29:540-549.e4. [PMID: 29477619 DOI: 10.1016/j.jvir.2017.11.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
118 Ho DWH, Chan LK, Chiu YT, Xu IMJ, Poon RTP, Cheung TT, Tang CN, Tang VWL, Lo ILO, Lam PWY, Yau DTW, Li MX, Wong CM, Ng IOL. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication. Gut 2017;66:1496-506. [PMID: 27974549 DOI: 10.1136/gutjnl-2016-312734] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 10.2] [Reference Citation Analysis]
119 Wang L, Min Z, Wang X, Hu M, Song D, Ren Z, Cheng Y, Wang Y. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand. Oncol Lett 2018;16:3341-50. [PMID: 30127933 DOI: 10.3892/ol.2018.8981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
120 Sarpel U, Spivack JH, Berger Y, Heskel M, Aycart SN, Sweeney R, Edwards MP, Labow DM, Kim E. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. HPB (Oxford) 2016;18:411-8. [PMID: 27154804 DOI: 10.1016/j.hpb.2016.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
121 Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018;10:108-14. [PMID: 29770170 DOI: 10.4251/wjgo.v10.i5.108] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
122 Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Corti A, Tredici M, Piccinno M, Giorgi L, Bartolozzi C, Bargellini I. Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World J Gastroenterol 2015;21:6518-25. [PMID: 26074690 DOI: 10.3748/wjg.v21.i21.6518] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
123 Wang Q, Bin C, Xue Q, Gao Q, Huang A, Wang K, Tang N. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis 2021;12:426. [PMID: 33931597 DOI: 10.1038/s41419-021-03718-4] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
124 Liao LZ, Chen CT, Li NC, Lin LC, Huang BS, Chang YH, Chow LP. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci 2020;22:E224. [PMID: 33379356 DOI: 10.3390/ijms22010224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
125 Ko SF, Yip HK, Zhen YY, Lee CC, Lee CC, Huang CC, Ng SH, Lin JW. Adipose-Derived Mesenchymal Stem Cell Exosomes Suppress Hepatocellular Carcinoma Growth in a Rat Model: Apparent Diffusion Coefficient, Natural Killer T-Cell Responses, and Histopathological Features. Stem Cells Int. 2015;2015:853506. [PMID: 26345219 DOI: 10.1155/2015/853506] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
126 Diaz-Beveridge R, Bruixola G, Lorente D, Caballero J, Rodrigo E, Segura Á, Akhoundova D, Giménez A, Aparicio J. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib. Clin Transl Oncol 2018;20:322-9. [PMID: 28801777 DOI: 10.1007/s12094-017-1720-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
127 Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, Goh BK, Wong JS, Tay KH, Goh AS, Yan SX, Loke KS, Thang SP, Gogna A, Too CW, Irani FG, Leong S, Lim KH, Thng CH. National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer. 2016;5:97-106. [PMID: 27386428 DOI: 10.1159/000367759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
128 Gupta N, Verma RK, Prinja S, Dhiman RK. Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India. J Clin Exp Hepatol 2019;9:468-75. [PMID: 31516263 DOI: 10.1016/j.jceh.2018.10.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
129 Wu B, Jiang Y, Zhu F, Sun D, Huang H. Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703. Oncol Lett 2016;11:2545-51. [PMID: 27073515 DOI: 10.3892/ol.2016.4243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
130 Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, Lin ZZ, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, Larson SM, Cheng AL, Carrasquilo JA. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol 2017;79:421-9. [PMID: 28120036 DOI: 10.1007/s00280-017-3241-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
131 Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol 2011;17:1685-9. [PMID: 21483627 DOI: 10.3748/wjg.v17.i13.1685] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
132 Conroy G, Salleron J, Belle A, Bensenane M, Nani A, Ayav A, Peiffert D, Lopez A, Baumann C, Barraud H, Bronowicki JP. The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. Oncotarget 2017;8:95853-64. [PMID: 29221172 DOI: 10.18632/oncotarget.21401] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
133 Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K. Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers (Basel). 2019;11:1769. [PMID: 31717674 DOI: 10.3390/cancers11111769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
134 Huang CC, Hwang JM, Tsai JH, Chen JH, Lin H, Lin GJ, Yang HL, Liu JY, Yang CY, Ye JC. Aqueous Ocimum gratissimum extract induces cell apoptosis in human hepatocellular carcinoma cells. Int J Med Sci 2020;17:338-46. [PMID: 32132869 DOI: 10.7150/ijms.39436] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
135 Zhang H, Li XX, Yang Y, Zhang Y, Wang HY, Zheng XFS. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology 2018;67:2271-86. [PMID: 29220539 DOI: 10.1002/hep.29715] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
136 Wang P, Jiang Z, Liu X, Yu K, Wang C, Li H, Zhong L. PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma. Cancer Med 2020;9:6972-83. [PMID: 32779397 DOI: 10.1002/cam4.3331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10:e0124434. [PMID: 25923439 DOI: 10.1371/journal.pone.0124434] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
138 Bort A, Sánchez BG, Mateos-Gómez PA, Vara-Ciruelos D, Rodríguez-Henche N, Díaz-Laviada I. Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib. Mol Oncol 2019;13:1311-31. [PMID: 30959553 DOI: 10.1002/1878-0261.12488] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
139 Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-17. [PMID: 24283303 DOI: 10.1111/ijcp.12352] [Cited by in Crossref: 154] [Cited by in F6Publishing: 138] [Article Influence: 19.3] [Reference Citation Analysis]
140 Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology 2013;57:1068-77. [PMID: 23112096 DOI: 10.1002/hep.26120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
141 Zhang B, Finn RS. Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer. 2016;5:221-232. [PMID: 27493897 DOI: 10.1159/000367763] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
142 Shao YY, Lu LC, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Br J Cancer. 2012;107:1672-1677. [PMID: 23059748 DOI: 10.1038/bjc.2012.466] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
143 Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A, Castiglione A, Ciccone G, Rizzetto M. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30:345. [PMID: 23263829 DOI: 10.1007/s12032-012-0345-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
144 Sung PS, Jang JW. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. Int J Mol Sci. 2018;19:3648. [PMID: 30463262 DOI: 10.3390/ijms19113648] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
145 Pircher A, Medinger M, Drevs J. Liver cancer: Targeted future options. World J Hepatol. 2011;3:38-44. [PMID: 21423913 DOI: 10.4254/wjh.v3.i2.38] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
146 Chen T, Huang H, Zhou Y, Geng L, Shen T, Yin S, Zhou L, Zheng S. HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways. J Exp Clin Cancer Res 2018;37:193. [PMID: 30111352 DOI: 10.1186/s13046-018-0866-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
147 Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D, Wang K, Xia Y, Shen F. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. Oncotarget 2016;7:83806-16. [PMID: 27566566 DOI: 10.18632/oncotarget.11514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
148 Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864. [PMID: 23737955 DOI: 10.1371/journal.pone.0063864] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 9.8] [Reference Citation Analysis]
149 Luo J, Jin K, Qian S, Ma X, Pan Z, Yao W, Zhang Z, Guo X, Yu X. Single institution experience of split course radiotherapy in patients with desmoid tumors. Onco Targets Ther 2019;12:1741-8. [PMID: 30881028 DOI: 10.2147/OTT.S189449] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
150 Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016;7:67142-67149. [PMID: 27613839 DOI: 10.18632/oncotarget.11565] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 19.3] [Reference Citation Analysis]
151 Dhanasekaran R, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep 2015;17:34. [PMID: 26238927 DOI: 10.1007/s11894-015-0459-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
152 Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D'Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015;141:1301-1309. [PMID: 25644863 DOI: 10.1007/s00432-015-1929-y] [Cited by in Crossref: 93] [Cited by in F6Publishing: 70] [Article Influence: 15.5] [Reference Citation Analysis]
153 Fang C, Xie H, Zhao J, Wang W, Hou H, Zhang B, Zhou D, Geng X. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma. Anticancer Drugs 2021;32:822-8. [PMID: 33783376 DOI: 10.1097/CAD.0000000000001074] [Reference Citation Analysis]
154 Casadei Gardini A, Puzzoni M, Montagnani F, Marisi G, Tamburini E, Cucchetti A, Solaini L, Foschi FG, Conti F, Ercolani G, Cascinu S, Scartozzi M. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. Onco Targets Ther. 2019;12:2981-2988. [PMID: 31118665 DOI: 10.2147/ott.s192572] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
155 Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010;29:2309-24. [PMID: 20228847 DOI: 10.1038/onc.2010.36] [Cited by in Crossref: 184] [Cited by in F6Publishing: 167] [Article Influence: 16.7] [Reference Citation Analysis]
156 Kim SH, Kim S, Nam BH, Lee SE, Kim CS, Seo IY, Kim TN, Hong SH, Kwon TG, Seo SI, Joo KJ, Song K, Kwak C, Chung J. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study. PLoS One 2015;10:e0135165. [PMID: 26308612 DOI: 10.1371/journal.pone.0135165] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
157 Xu J, Ji L, Ruan Y, Wan Z, Lin Z, Xia S, Tao L, Zheng J, Cai L, Wang Y, Liang X, Cai X. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma. Signal Transduct Target Ther 2021;6:190. [PMID: 34001851 DOI: 10.1038/s41392-021-00594-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
158 Cao M, Prima V, Nelson D, Svetlov S. Composite fatty acid ether amides suppress growth of liver cancer cells in vitro and in an in vivo allograft mouse model. Cell Oncol (Dordr) 2013;36:247-57. [PMID: 23619943 DOI: 10.1007/s13402-013-0132-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
159 Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K;  Real-life Practice Experts for HCC (RELPEC) Study Group;  HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med. 2019;8:137-146. [PMID: 30575325 DOI: 10.1002/cam4.1909] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 20.0] [Reference Citation Analysis]
160 Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK; Asia-Pacific Hepatocellular Carcinoma Trials Group. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 2016;16:856. [PMID: 27821083 DOI: 10.1186/s12885-016-2868-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
161 Koga Y, Beppu T, Imai K, Kuramoto K, Miyata T, Kitano Y, Nakagawa S, Okabe H, Okabe K, Yamashita YI, Chikamoto A, Baba H. Complete remission of advanced hepatocellular carcinoma following transient chemoembolization and portal vein ligation. Surg Case Rep 2018;4:102. [PMID: 30159613 DOI: 10.1186/s40792-018-0510-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 2014;19:394-402. [PMID: 24652387 DOI: 10.1634/theoncologist.2013-0114] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 12.3] [Reference Citation Analysis]
163 Saka H, Kitagawa C, Kogure Y, Takahashi Y, Fujikawa K, Sagawa T, Iwasa S, Takahashi N, Fukao T, Tchinou C, Landers D, Yamada Y. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Invest New Drugs 2017;35:451-62. [PMID: 28070720 DOI: 10.1007/s10637-016-0416-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
164 Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. PLoS One. 2014;9:e96620. [PMID: 24817002 DOI: 10.1371/journal.pone.0096620] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
165 Wang WJ, Wang H, Hua TY, Song W, Zhu J, Wang JJ, Huang YQ, Ding ZL. Establishment of a Prognostic Model Using Immune-Related Genes in Patients With Hepatocellular Carcinoma. Front Genet 2020;11:55. [PMID: 32158466 DOI: 10.3389/fgene.2020.00055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
166 Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. Int J Mol Sci. 2019;20. [PMID: 30889843 DOI: 10.3390/ijms] [Cited by in Crossref: 22] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
167 Yang KL, Chi MS, Ko HL, Huang YY, Huang SC, Lin YM, Chi KH. Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Radiat Oncol 2021;16:18. [PMID: 33472666 DOI: 10.1186/s13014-020-01742-w] [Reference Citation Analysis]
168 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021;27:2434-57. [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Zhu LZ, Xu HF, Yang RJ. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. Biomed Res Int 2021;2021:6670367. [PMID: 34337041 DOI: 10.1155/2021/6670367] [Reference Citation Analysis]
170 Mo HN, Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med 2017;3:148-53. [PMID: 29063069 DOI: 10.1016/j.cdtm.2017.06.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 13.3] [Reference Citation Analysis]
171 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 106] [Article Influence: 11.3] [Reference Citation Analysis]
172 Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BKP, Ooi LL, Hui KM. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov 2017;3:17058. [PMID: 28900541 DOI: 10.1038/cddiscovery.2017.58] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
173 Kuppusamy P, Nagalingam A, Muniraj N, Saxena NK, Sharma D. Concomitant activation of ETS-like transcription factor-1 and Death Receptor-5 via extracellular signal-regulated kinase in withaferin A-mediated inhibition of hepatocarcinogenesis in mice. Sci Rep 2017;7:17943. [PMID: 29263422 DOI: 10.1038/s41598-017-18190-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
174 Tse AP, Sze KM, Shea QT, Chiu EY, Tsang FH, Chiu DK, Zhang MS, Lee D, Xu IM, Chan CY, Koh HY, Wong CM, Zheng YP, Ng IO, Wong CC. Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. Oncogenesis. 2018;7:44. [PMID: 29799025 DOI: 10.1038/s41389-018-0052-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
175 Zhang J, Zong Y, Xu GZ, Xing K. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J 2016;37:1184-90. [PMID: 27761555 DOI: 10.15537/smj.2016.11.16267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
176 Deng T, Hu B, Jin C, Tong Y, Zhao J, Shi Z, Zhang T, Deng L, Sun Z, Chen G, Wang Y. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma. J Cell Mol Med 2021;25:6618-33. [PMID: 34085405 DOI: 10.1111/jcmm.16666] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
177 Wang HW, Chuang PH, Su WP, Kao JT, Hsu WF, Lin CC, Huang GT, Lin JT, Lai HC, Peng CY. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3758. [PMID: 34359658 DOI: 10.3390/cancers13153758] [Reference Citation Analysis]
178 Wang J, Chen X, Tian Y, Zhu G, Qin Y, Chen X, Pi L, Wei M, Liu G, Li Z, Chen C, Lv Y, Cai G. Six-gene signature for predicting survival in patients with head and neck squamous cell carcinoma. Aging (Albany NY) 2020;12:767-83. [PMID: 31927533 DOI: 10.18632/aging.102655] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
179 da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, Hoff PM, Sabbaga J. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31:264. [PMID: 25273866 DOI: 10.1007/s12032-014-0264-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
180 Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study. J Cancer 2019;10:1189-96. [PMID: 30854128 DOI: 10.7150/jca.28994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
181 Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E, Granito A. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol 2018;5:HEP01. [PMID: 30302192 DOI: 10.2217/hep-2017-0020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
182 Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, Sho Y, Tahara K, Higashi H, Tamai T. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2:433-441. [PMID: 22977522 DOI: 10.3892/etm.2011.237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
183 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
184 Liao Y, Zheng Y, He W, Li Q, Shen J, Hong J, Zou R, Qiu J, Li B, Yuan Y. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett 2017;13:984-92. [PMID: 28356989 DOI: 10.3892/ol.2016.5525] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
185 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
186 Wang H, Rao B, Lou J, Li J, Liu Z, Li A, Cui G, Ren Z, Yu Z. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:55. [PMID: 32117981 DOI: 10.3389/fcell.2020.00055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 24.0] [Reference Citation Analysis]
187 Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM, Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P, Frassineti GL. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016;7:27988-27999. [PMID: 27058899 DOI: 10.18632/oncotarget.8569] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
188 El Dika I, Khalil DN, Abou-Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer 2019;125:3312-9. [PMID: 31290997 DOI: 10.1002/cncr.32076] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
189 Tomonari T, Takeishi S, Taniguchi T, Tanaka T, Tanaka H, Fujimoto S, Kimura T, Okamoto K, Miyamoto H, Muguruma N, Takayama T. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget 2016;7:7207-15. [PMID: 26769852 DOI: 10.18632/oncotarget.6889] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
190 Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
191 Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010;1:515-29. [PMID: 21317448 DOI: 10.18632/oncotarget.101006] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
192 Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer. 2012;1:62-70. [PMID: 24159574 DOI: 10.1159/000342402] [Cited by in Crossref: 39] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
193 Ansari D, Andersson R. Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors. World J Gastroenterol. 2012;18:1003-1008. [PMID: 22416173 DOI: 10.3748/wjg.v18.i10.1003] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
194 Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer 2021;10:224-39. [PMID: 34239809 DOI: 10.1159/000514400] [Reference Citation Analysis]
195 Kaneko R, Nakazaki N, Omori R, Yano Y, Ogawa M, Sato Y. The Effect of New Therapeutic and Diagnostic Agents on the Prognosis of Hepatocellular Carcinoma in Japan – An Analysis of Data from the Kanagawa Cancer Registry. Asian Pac J Cancer Prev 2017;18:2471-6. [PMID: 28952279 DOI: 10.22034/APJCP.2017.18.9.2471] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
196 Zhao W, Ma B, Tian Z, Han H, Tang J, Dong B, An G, Cao B, Wang B. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance. Br J Cancer 2021;124:1237-48. [PMID: 33473171 DOI: 10.1038/s41416-020-01240-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
197 Lee J, Yoon WS, Koom WS, Rim CH. Role of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South Korea. Cancer Manag Res 2019;11:1373-82. [PMID: 30809102 DOI: 10.2147/CMAR.S193761] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
198 Cabrera R. Systemic targeted therapy beyond sorafenib. Clin Liver Dis (Hoboken) 2012;1:212-6. [PMID: 31186890 DOI: 10.1002/cld.128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
199 Zhang Y, Fan W, Zhu K, Lu L, Fu S, Huang J, Wang Y, Yang J, Huang Y, Yao W, Li J. Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. Oncotarget 2015;6:24550-9. [PMID: 26093084 DOI: 10.18632/oncotarget.4076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
200 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
201 Wang C, Jin H, Gao D, Wang L, Evers B, Xue Z, Jin G, Lieftink C, Beijersbergen RL, Qin W, Bernards R. A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell Res 2018;28:690-2. [PMID: 29507396 DOI: 10.1038/s41422-018-0020-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
202 Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014;20:12581-7. [PMID: 25253961 DOI: 10.3748/wjg.v20.i35.12581] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
203 Sakamoto K, Nagano H. Outcomes of surgery for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium. Surg Today 2018;48:819-24. [PMID: 29279997 DOI: 10.1007/s00595-017-1619-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
204 Liang L, Quan B, Wu H, Diao YK, Li J, Chen TH, Zhang YM, Zhou YH, Zhang WG, Wang H, Serenari M, Cescon M, Schwartz M, Zeng YY, Liang YJ, Jia HD, Xing H, Li C, Wang MD, Yan WT, Chen WY, Lau WY, Zhang CW, Pawlik TM, Huang DS, Shen F, Yang T. Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study. Hepatol Int 2021;15:459-71. [PMID: 33534082 DOI: 10.1007/s12072-021-10140-7] [Reference Citation Analysis]
205 Sirohi B, Shrikhande SV, Gaikwad V, Patel A, Patkar S, Goel M, Bal M, Sharma A, Shrimali RK, Bhatia V, Kulkarni S, Srivastava DN, Kaur T, Dhaliwal RS, Rath GK; Indian Council of Medical Research Guidelines Working Group. Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res 2020;152:468-74. [PMID: 33707388 DOI: 10.4103/ijmr.IJMR_404_20] [Reference Citation Analysis]
206 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Tighe SP, Iqbal U, Fernandes CT, Ahmed A. Treatment of inoperable hepatocellular carcinoma with immunotherapy. BMJ Case Rep 2019;12:e229744. [PMID: 31352386 DOI: 10.1136/bcr-2019-229744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kanayama M, Matsui T, Kikuchi Y, Ishii K, Igarashi Y. Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report. Oncol Lett. 2014;7:50-52. [PMID: 24348819 DOI: 10.3892/ol.2013.1664] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
209 Chen F, Zhong Z, Tan HY, Wang N, Feng Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers (Basel) 2020;12:E1734. [PMID: 32610709 DOI: 10.3390/cancers12071734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
210 Jariwala N, Sarkar D. Emerging role of lncRNA in cancer: a potential avenue in molecular medicine. Ann Transl Med 2016;4:286. [PMID: 27569205 DOI: 10.21037/atm.2016.06.27] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
211 Facciorusso A, Bargellini I, Cela M, Cincione I, Sacco R. Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers (Basel) 2020;12:E897. [PMID: 32272656 DOI: 10.3390/cancers12040897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
212 Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Katano Y, Hirooka Y, Ishikawa T, Nakano I, Goto H. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS One. 2015;10:e0138776. [PMID: 26421430 DOI: 10.1371/journal.pone.0138776] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
213 Chu KK, Cheung TT. Update in management of hepatocellular carcinoma in Eastern population. World J Hepatol. 2015;7:1562-1571. [PMID: 26085915 DOI: 10.4254/wjh.v7.i11.1562] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
214 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 159] [Article Influence: 24.1] [Reference Citation Analysis]
215 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
216 Yoon HI, Jung I, Han KH, Seong J. The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma. Oncotarget 2016;7:62715-25. [PMID: 27486881 DOI: 10.18632/oncotarget.10908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
217 Li LM, Liu H, Liu XH, Hu HB, Liu SM. Clinical significance of exosomal miRNAs and proteins in three human cancers with high mortality in China. Oncol Lett 2019;17:11-22. [PMID: 30655733 DOI: 10.3892/ol.2018.9631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
218 Matoba M, Tsuchiya H, Kondo T, Ota K. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: a single-institutional study. J Radiat Res. 2020;61:776-783. [PMID: 32845298 DOI: 10.1093/jrr/rraa067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer 2018;18:1131. [PMID: 30453925 DOI: 10.1186/s12885-018-5081-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
220 Ji L, Lin Z, Wan Z, Xia S, Jiang S, Cen D, Cai L, Xu J, Cai X. miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR. Cell Death Dis 2020;11:250. [PMID: 32313144 DOI: 10.1038/s41419-020-2413-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
221 Wang H, Wang H, Yu Z, Liu H. Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials. Onco Targets Ther 2018;11:5195-201. [PMID: 30214225 DOI: 10.2147/OTT.S171918] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
222 Ünal E, İdilman İS, Akata D, Özmen MN, Karçaaltıncaba M. Microvascular invasion in hepatocellular carcinoma. Diagn Interv Radiol 2016;22:125-32. [PMID: 26782155 DOI: 10.5152/dir.2015.15125] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
223 Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer 2015;22:877-87. [PMID: 26370187 DOI: 10.1530/ERC-15-0252] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 6.2] [Reference Citation Analysis]
224 Fonseca GM, Varella AD, Coelho FF, Abe ES, Dumarco RB, Herman P. Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma. World J Gastrointest Surg 2014;6:107-11. [PMID: 24976904 DOI: 10.4240/wjgs.v6.i6.107] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
225 Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W. Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea. J Korean Med Sci 2016;31:403-9. [PMID: 26955241 DOI: 10.3346/jkms.2016.31.3.403] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
226 Sanda M, Tamai H, Deguchi H, Mori Y, Moribata K, Shingaki N, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Acalculous cholecystitis in a patient with hepatocellular carcinoma on sorafenib. ISRN Gastroenterol 2011;2011:201529. [PMID: 21991498 DOI: 10.5402/2011/201529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
227 Lai SC, Su YT, Chi CC, Kuo YC, Lee KF, Wu YC, Lan PC, Yang MH, Chang TS, Huang YH. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res 2019;38:474. [PMID: 31771617 DOI: 10.1186/s13046-019-1442-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
228 Liu TP, Lo HL, Wei LS, Hsiao HH, Yang PM. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells. Anticancer Drugs 2015;26:139-47. [PMID: 25203626 DOI: 10.1097/CAD.0000000000000166] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 6.2] [Reference Citation Analysis]
229 Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World J Gastroenterol 2017;23:2448-52. [PMID: 28428725 DOI: 10.3748/wjg.v23.i13.2448] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
230 Qin S, Gong X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. Hepat Oncol 2016;3:71-81. [PMID: 30191027 DOI: 10.2217/hep.15.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
231 Barbier L, Muscari F, Le Guellec S, Pariente A, Otal P, Suc B. Liver resection after downstaging hepatocellular carcinoma with sorafenib. Int J Hepatol. 2011;2011:791013. [PMID: 22135750 DOI: 10.4061/2011/791013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
232 Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS One 2018;13:e0207132. [PMID: 30408106 DOI: 10.1371/journal.pone.0207132] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
233 Ying ZL, Li XJ, Dang H, Wang F, Xu XY. Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells. Exp Ther Med. 2014;7:1354-1358. [PMID: 24940438 DOI: 10.3892/etm] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
234 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
235 Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329-336. [PMID: 23396206 DOI: 10.1038/nm.3089] [Cited by in Crossref: 449] [Cited by in F6Publishing: 421] [Article Influence: 56.1] [Reference Citation Analysis]
236 Nagl L, Horvath L, Pircher A, Wolf D. Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives. Front Cell Dev Biol 2020;8:766. [PMID: 32974337 DOI: 10.3389/fcell.2020.00766] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
237 Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz JE, Baker SD. Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clin Cancer Res 2019;25:7320-30. [PMID: 31455680 DOI: 10.1158/1078-0432.CCR-19-0470] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
238 Abdel-Rahman O. Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study. J Cancer Res Clin Oncol 2018;144:901-8. [PMID: 29455421 DOI: 10.1007/s00432-018-2610-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
239 Raoul JL, Frenel JS, Raimbourg J, Gilabert M. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepat Oncol 2019;6:HEP11. [PMID: 31244990 DOI: 10.2217/hep-2019-0001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
240 Allaire M, Nault JC. Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:53-5. [PMID: 30881965 DOI: 10.21037/hbsn.2018.10.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Okusaka T, Ueno H, Ikeda M, Takezako Y, Morizane C. Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma. Cancer Sci. 2012;103:1524-1530. [PMID: 22587457 DOI: 10.1111/j.1349-7006.2012.02334] [Reference Citation Analysis]
242 Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an italian in-field experience. Dig Dis Sci. 2015;60:1465-1473. [PMID: 25399329 DOI: 10.1007/s10620-014-3427-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
243 Ting CT, Cheng YY, Tsai TH. Preclinical Pharmacokinetic Interaction and Histopathological Analyses of Hedyotis diffusa on Sorafenib in Rats. ACS Omega 2021;6:3060-7. [PMID: 33553923 DOI: 10.1021/acsomega.0c05461] [Reference Citation Analysis]
244 Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Eguchi S, Yamashita T, Kudo M. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. Liver Cancer 2019;8:403-11. [PMID: 31768348 DOI: 10.1159/000495944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
245 Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, Huang J. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel) 2018;10:E516. [PMID: 30558224 DOI: 10.3390/cancers10120516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
246 Liao J, Jin H, Li S, Xu L, Peng Z, Wei G, Long J, Guo Y, Kuang M, Zhou Q, Peng S. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:454. [PMID: 31694662 DOI: 10.1186/s13046-019-1419-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
247 Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018;379:54-63. [PMID: 29972759 DOI: 10.1056/NEJMoa1717002] [Cited by in Crossref: 703] [Cited by in F6Publishing: 397] [Article Influence: 234.3] [Reference Citation Analysis]
248 Wang M, Wu M, Yang T. The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma. EBioMedicine 2019;40:11-2. [PMID: 30651221 DOI: 10.1016/j.ebiom.2019.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
249 Zhang Y, Gao X, Zhu Y, Kadel D, Sun H, Chen J, Luo Q, Sun H, Yang L, Yang J, Sheng Y, Zheng Y, Zhu K, Dong Q, Qin L. The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2018;37:93. [PMID: 29712569 DOI: 10.1186/s13046-018-0750-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
250 Sueangoen N, Tantiwetrueangdet A, Panvichian R. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci 2020;10:41. [PMID: 32190291 DOI: 10.1186/s13578-020-00407-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
251 Kan X, Liang B, Zhou G, Xiong B, Pan F, Ren Y, Cao Y, Wang J, Yang F, Zheng C. Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2020;10:970. [PMID: 32733791 DOI: 10.3389/fonc.2020.00970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
252 Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer 2017;6:360-74. [PMID: 29234639 DOI: 10.1159/000481315] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
253 Kong Y, Sun L, Hou Z, Zhang Y, Chen P, Cui Y, Zhu X, Song T, Li Q, Li H, Zhang T, Qin L. Apatinib is effective for treatment of advanced hepatocellular carcinoma. Oncotarget. 2017;8:105596-105605. [PMID: 29285275 DOI: 10.18632/oncotarget.22337] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
254 Chai ZT, Zhang XP, Shao M, Ao JY, Chen ZH, Zhang F, Hu YR, Zhong CQ, Lin JH, Fang KP, Wu MC, Lau WY, Cheng SQ. Impact of splenomegaly and splenectomy on prognosis in hepatocellular carcinoma with portal vein tumor thrombus treated with hepatectomy. Ann Transl Med 2021;9:247. [PMID: 33708874 DOI: 10.21037/atm-20-2229] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Li XD, Wang Z, Wang XR, Shao D, Zhang X, Li L, Ge MF, Chang ZM, Dong WF. Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition. Int J Nanomedicine 2019;14:3967-82. [PMID: 31239666 DOI: 10.2147/IJN.S206044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
256 El Shorbagy S, abuTaleb F, Labib HA, Ebian H, Harb OA, Mohammed MS, Rashied HA, Elbana KA, Haggag R. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination. J Gastrointest Cancer 2021;52:269-79. [PMID: 32212089 DOI: 10.1007/s12029-020-00389-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
257 Personeni N, Rimassa L, Pressiani T, Destro A, Ligorio C, Tronconi MC, Bozzarelli S, Carnaghi C, Di Tommaso L, Giordano L, Roncalli M, Santoro A. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2013;139:1179-1187. [PMID: 23568548 DOI: 10.1007/s00432-013-1429-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
258 Xu J, Lin H, Li G, Sun Y, Chen J, Shi L, Cai X, Chang C. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals. EBioMedicine 2016;12:55-67. [PMID: 27688096 DOI: 10.1016/j.ebiom.2016.07.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
259 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol. 2015;7:1913-1920. [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
260 Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T. Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. J Gastroenterol. 2012;47:343-346. [PMID: 22183859 DOI: 10.1007/s00535-011-0511-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
261 Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, Liu QX, Luo JJ, Liu LX, Liu R, Qian S. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer. 2012;12:263. [PMID: 22721173 DOI: 10.1186/1471-2407-12-263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
262 Abdel-rahman O, Elsayed ZA. Combination Trans Arterial Chemoembolization (TACE) Plus Sorafenib for the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review of the Literature. Dig Dis Sci 2013;58:3389-96. [DOI: 10.1007/s10620-013-2872-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 6.3] [Reference Citation Analysis]
263 Liu YE, Zong J, Chen XJ, Zhang R, Ren XC, Guo ZJ, Liu CX, Lin Q. Cryoablation combined with radiotherapy for hepatic malignancy: Five case reports. World J Gastrointest Oncol 2020;12:237-47. [PMID: 32104554 DOI: 10.4251/wjgo.v12.i2.237] [Reference Citation Analysis]
264 Lemieux S, Buies A, F Turgeon A, Hallet J, Daigle G, Côté F, Provencher S. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2021;16:e0247958. [PMID: 33662011 DOI: 10.1371/journal.pone.0247958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med. 2012;4:139ra84. [PMID: 22539746 DOI: 10.1126/scitranslmed.3003923] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 6.9] [Reference Citation Analysis]
266 Lee S, Yoon SH, Park JY, Kim DY, Ahn SH, Han K, Choi HJ. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Invest New Drugs 2012;30:1150-7. [DOI: 10.1007/s10637-011-9634-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
267 Dong N, Shi X, Wang S, Gao Y, Kuang Z, Xie Q, Li Y, Deng H, Wu Y, Li M, Li JL. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer 2019;121:22-33. [PMID: 31130723 DOI: 10.1038/s41416-019-0482-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 16.5] [Reference Citation Analysis]
268 Rim CH, Yoon WS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. Onco Targets Ther. 2018;11:2865-2874. [PMID: 29844684 DOI: 10.2147/ott.s164651] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
269 Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS. Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib. JGH Open 2019;3:10-6. [PMID: 30834335 DOI: 10.1002/jgh3.12096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
270 Qin S, Kruger E, Tan SC, Cheng S, Wang N, Liang J. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Eff Resour Alloc 2018;16:29. [PMID: 30087583 DOI: 10.1186/s12962-018-0112-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
271 Xiang Q, Zhen Z, Deng DY, Wang J, Chen Y, Li J, Zhang Y, Wang F, Chen N, Chen H, Chen Y. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:118. [PMID: 26458953 DOI: 10.1186/s13046-015-0238-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
272 Ogasawara S, Choo SP, Li JT, Yoo C, Wang B, Lee D, Chow PKH. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers (Basel) 2021;13:2626. [PMID: 34071818 DOI: 10.3390/cancers13112626] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis. Cancer Sci. 2020;111:2747-2759. [PMID: 32449239 DOI: 10.1111/cas.14497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
274 Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma 2019;6:31-9. [PMID: 30775342 DOI: 10.2147/JHC.S168953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 11.5] [Reference Citation Analysis]
275 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol. 2015;21:10336-10347. [PMID: 26420960 DOI: 10.3748/wjg.v21.i36.10336] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
276 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 21.0] [Reference Citation Analysis]
277 Panvichian R, Tantiwetrueangdet A, Sornmayura P, Leelaudomlipi S. Missense Mutations in Exons 18-24 of EGFR in Hepatocellular Carcinoma Tissues. Biomed Res Int 2015;2015:171845. [PMID: 26436086 DOI: 10.1155/2015/171845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
278 Xiao Y, Sun L, Fu Y, Huang Y, Zhou R, Hu X, Zhou P, Quan J, Li N, Fan XG. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo. BMC Cancer. 2017;17:857. [PMID: 29246127 DOI: 10.1186/s12885-017-3868-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
279 Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol. 2014;20:235-241. [PMID: 24415877 DOI: 10.3748/wjg.v20.i1.235] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
280 Zhang EL, Zhang ZY, Li J, Huang ZY. Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient. Onco Targets Ther 2020;13:12477-87. [PMID: 33311988 DOI: 10.2147/OTT.S284092] [Reference Citation Analysis]
281 Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. [PMID: 26955390 DOI: 10.1155/2016/5942306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
282 Choi WM, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Park SR, Ryu MH, Ryoo BY, Lee SJ, Kim KM. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. Hepatol Commun. 2020;4:1073-1086. [PMID: 32626838 DOI: 10.1002/hep4.1523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
283 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Yu Z, Feng H, Sun X, Zhuo Y, Li M, Zhou Z, Huang L, Jiang Y, Zhu X, Zhang X, Le F, Zheng C, Cheng AS, Gao Y. Bufalin suppresses hepatocarcinogenesis by targeting β-catenin/TCF signaling via cell cycle-related kinase. Sci Rep 2018;8:3891. [PMID: 29497076 DOI: 10.1038/s41598-018-22113-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
285 Kang D, Han Z, Oh GH, Joo Y, Choi HJ, Song JJ. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. Yonsei Med J 2017;58:899-909. [PMID: 28792132 DOI: 10.3349/ymj.2017.58.5.899] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
286 Cohen GS, Black M. Multidisciplinary management of hepatocellular carcinoma: a model for therapy. J Multidiscip Healthc. 2013;6:189-195. [PMID: 23690690 DOI: 10.2147/jmdh.s41206] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
287 Køstner AH, Sorensen M, Olesen RK, Grønbæk H, Lassen U, Ladekarl M. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. ScientificWorldJournal 2013;2013:931972. [PMID: 23431262 DOI: 10.1155/2013/931972] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
288 Shao GL, Zheng JP, Guo LW, Chen YT, Zeng H, Yao Z. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study. Medicine (Baltimore) 2017;96:e5518. [PMID: 28099329 DOI: 10.1097/MD.0000000000005518] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
289 Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus. Onco Targets Ther. 2016;9:3841-3848. [PMID: 27390524 DOI: 10.2147/ott.s104307] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
290 Jiang H, Ning G, Wang Y, Lv W. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response. Dis Markers 2021;2021:5576683. [PMID: 34221187 DOI: 10.1155/2021/5576683] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
291 Ye DW, Zhang HL. Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma. Onco Targets Ther 2014;7:925-35. [PMID: 24944516 DOI: 10.2147/OTT.S41828] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
292 Lee JI, Kim JK, Kim DY, Ahn SH, Park JY, Kim SU, Kim BK, Han KH, Lee KS. Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. Clin Exp Metastasis. 2014;31:475-482. [PMID: 24496959 DOI: 10.1007/s10585-014-9641-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
293 Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N. Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. Cancers (Basel) 2020;12:E3048. [PMID: 33092011 DOI: 10.3390/cancers12103048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
294 Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Weiss A, Miles S, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz BE, Santoro A. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget. 2016;7:72622-72633. [PMID: 27579536 DOI: 10.18632/oncotarget.11621] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
295 Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiol med 2014;119:215-21. [DOI: 10.1007/s11547-013-0332-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
296 Lee M, Jeon JY, Neugent ML, Kim JW, Yun M. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. Clin Exp Metastasis. 2017;34:251-260. [PMID: 28429188 DOI: 10.1007/s10585-017-9847-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
297 Chen MY, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Tsang NM, Chan KM, Lee WC. Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Biomed Res Int 2016;2016:6017406. [PMID: 27999803 DOI: 10.1155/2016/6017406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
298 Burak KW, Kneteman NM. An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithm. Can J Gastroenterol 2010;24:643-50. [PMID: 21157578 DOI: 10.1155/2010/410574] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
299 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
300 Shomura M, Okabe H, Sato E, Fukai K, Shiraishi K, Hirose S, Tsuruya K, Arase Y, Anzai K, Kagawa T. Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers (Basel) 2020;12:E3078. [PMID: 33105621 DOI: 10.3390/cancers12113078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
301 Que J, Kuo HT, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC. Clinical outcomes and prognostic factors of cyberknife stereotactic body radiation therapy for unresectable hepatocellular carcinoma. BMC Cancer 2016;16:451. [PMID: 27405814 DOI: 10.1186/s12885-016-2512-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
302 Liu C, Wu H, Mao Y, Chen W, Chen S. Exosomal microRNAs in hepatocellular carcinoma. Cancer Cell Int 2021;21:254. [PMID: 33964930 DOI: 10.1186/s12935-021-01941-9] [Reference Citation Analysis]
303 Li W, Wang Y, Kellner DB, Zhao L, Xu L, Gao Q. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncol Lett. 2016;12:707-714. [PMID: 27347204 DOI: 10.3892/ol.2016.4629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
304 Akutsu N, Sasaki S, Takagi H, Motoya M, Shitani M, Igarashi M, Hirayama D, Wakasugi H, Yamamoto H, Kaneto H, Yonezawa K, Yawata A, Adachi T, Hamamoto Y, Shinomura Y. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. Int J Clin Oncol 2015;20:105-10. [PMID: 24744262 DOI: 10.1007/s10147-014-0691-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
305 Yazdani HO, Huang H, Tsung A. Autophagy: Dual Response in the Development of Hepatocellular Carcinoma. Cells. 2019;8. [PMID: 30695997 DOI: 10.3390/cells8020091] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
306 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
307 Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L, Ponziani F, De Gaetano A, Siciliano M, Basso M, Zocco MA, Rapaccini G, Posa A, Carchesio F, Biolato M, Giuliante F, Gasbarrini A, Manfredi R; HepatoCatt Study Group. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29:1285-1292. [PMID: 30171360 DOI: 10.1007/s00330-018-5692-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
308 Callegari E, Gramantieri L, Domenicali M, D’Abundo L, Sabbioni S, Negrini M. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2015;22:46-57. [PMID: 25190143 DOI: 10.1038/cdd.2014.136] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 12.1] [Reference Citation Analysis]
309 Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15:1198-1204. [PMID: 21036880 DOI: 10.1634/theoncologist.2010-0180] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
310 Yan M, Dongmei B, Jingjing Z, Xiaobao J, Jie W, Yan W, Jiayong Z. Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma. Sci Rep 2017;7:14074. [PMID: 29075040 DOI: 10.1038/s41598-017-14320-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
311 Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y. Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer 2019;8:505-19. [PMID: 31799207 DOI: 10.1159/000503032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
312 Galanakis N, Kehagias E, Matthaiou N, Samonakis D, Tsetis D. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol 2018;5:HEP07. [PMID: 31293775 DOI: 10.2217/hep-2018-0001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
313 Chen M, Therneau T, Orsini LS, Qiao YL. Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. BMC Gastroenterol. 2011;11:53. [PMID: 21569429 DOI: 10.1186/1471-230x-11-53] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
314 Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16:149. [PMID: 28854942 DOI: 10.1186/s12943-017-0712-x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 29.3] [Reference Citation Analysis]
315 Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009;15:263-268. [PMID: 19672141 DOI: 10.1097/PPO.0b013e3181af5e35] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
316 Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M, Rosenzweig B, Nierodzik M, Hochster H, Muggia F, Abbadessa G, Lewis J, Zhu AX. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs 2010;28:670-6. [PMID: 19565187 DOI: 10.1007/s10637-009-9286-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
317 Woo HY, Heo J. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future. Clin Mol Hepatol. 2015;21:344-348. [PMID: 26770921 DOI: 10.3350/cmh.2015.21.4.344] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
318 Mu W, Jiang D, Mu S, Liang S, Liu Y, Zhang N. Promoting Early Diagnosis and Precise Therapy of Hepatocellular Carcinoma by Glypican-3-Targeted Synergistic Chemo-Photothermal Theranostics. ACS Appl Mater Interfaces 2019;11:23591-604. [DOI: 10.1021/acsami.9b05526] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
319 Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW, Busuttil RW. Major challenges limiting liver transplantation in the United States. Am J Transplant. 2011;11:1773-1784. [PMID: 21672146 DOI: 10.1111/j.1600-6143.2011.03587.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 91] [Article Influence: 11.0] [Reference Citation Analysis]
320 Oyama K, Koda M, Sugihara T, Kishina M, Miyoshi K, Okamoto T, Hodotsuka M, Fujise Y, Matono T, Tokunaga S, Okamoto K, Hosho K, Okano J, Murawaki Y. Rapid and early α-fetoprotein and des-γ-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol 2015;3:655-62. [PMID: 26137283 DOI: 10.3892/mco.2015.523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
321 Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010;2:54ra77. [PMID: 20962331 DOI: 10.1126/scitranslmed.3001338] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
322 Guo XX, Li XP, Zhou P, Li DY, Lyu XT, Chen Y, Lyu YW, Tian K, Yuan DZ, Ran JH, Chen DL, Jiang R, Li J. Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway. Int J Mol Sci 2018;19:E3419. [PMID: 30384473 DOI: 10.3390/ijms19113419] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
323 Qu K, Liu T, Lin T, Zhang X, Cui R, Liu S, Meng F, Zhang J, Tai M, Wan Y, Liu C. Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget 2016;7:67650-60. [PMID: 27588502 DOI: 10.18632/oncotarget.11767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
324 Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30:655. [PMID: 23824645 DOI: 10.1007/s12032-013-0655-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
325 Yen TH, Chang CH, Shiu SI. Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma. Case Rep Gastroenterol 2020;14:367-72. [PMID: 32884512 DOI: 10.1159/000508583] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Yang X, Xia W, Chen L, Wu CX, Zhang CC, Olson P, Wang XQ. Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma. Oncotarget 2018;9:34996-5007. [PMID: 30405889 DOI: 10.18632/oncotarget.26209] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
327 Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y, Okusaka T. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol 2014;49:932-40. [PMID: 23793266 DOI: 10.1007/s00535-013-0853-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
328 Peng HS, Liao MB, Zhang MY, Xie Y, Xu L, Zhang YJ, Zheng XF, Wang HY, Chen YF. Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells. PLoS One 2014;9:e100814. [PMID: 24956259 DOI: 10.1371/journal.pone.0100814] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
329 Ni JY, Liu SS, Sun HL, Wang WD, Zhong ZL, Hou SN, Chen YT, Xu LF. Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population. Onco Targets Ther 2018;11:7883-94. [PMID: 30464535 DOI: 10.2147/OTT.S156844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
330 El-Khoueiry A. The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:311-317. [PMID: 28561676 DOI: 10.14694/edbk_175230] [Cited by in Crossref: 9] [Article Influence: 2.3] [Reference Citation Analysis]
331 Gaba RC, Elkhadragy L, Boas FE, Chaki S, Chen HH, El-Kebir M, Garcia KD, Giurini EF, Guzman G, LoBianco FV, Neto MF, Newson JL, Qazi A, Regan M, Rund LA, Schwind RM, Stewart MC, Thomas FM, Whiteley HE, Wu J, Schook LB, Schachtschneider KM. Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget 2020;11:2686-701. [PMID: 32733642 DOI: 10.18632/oncotarget.27647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
332 Marino D, Zichi C, Audisio M, Sperti E, Di Maio M. Second-line treatment options in hepatocellular carcinoma. Drugs Context 2019;8:212577. [PMID: 31024634 DOI: 10.7573/dic.212577] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
333 Chai ZT, Kong J, Zhu XD, Zhang YY, Lu L, Zhou JM, Wang LR, Zhang KZ, Zhang QB, Ao JY, Wang M, Wu WZ, Wang L, Tang ZY, Sun HC. MicroRNA-26a inhibits angiogenesis by down-regulating VEGFA through the PIK3C2α/Akt/HIF-1α pathway in hepatocellular carcinoma. PLoS One 2013;8:e77957. [PMID: 24194905 DOI: 10.1371/journal.pone.0077957] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
334 Nakazawa T, Hidaka H, Shibuya A, Okuwaki Y, Tanaka Y, Takada J, Minamino T, Watanabe M, Kokubu S, Koizumi W. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14:84. [PMID: 24886354 DOI: 10.1186/1471-230x-14-84] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
335 Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg 2012;16:874-81. [PMID: 21975686 DOI: 10.1007/s11605-011-1710-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
336 Li L, Kan X, Zhao Y, Liang B, Ye T, Yang L, Zheng C. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. Int J Med Sci 2021;18:2276-84. [PMID: 33967603 DOI: 10.7150/ijms.55510] [Reference Citation Analysis]
337 Sharma H. Role of external beam radiation therapy in management of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S122-S125. [PMID: 25755603 DOI: 10.1016/j.jceh.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
338 He W, Zheng Y, Zou R, Shen J, Yang J, Qiu J, Tao Q, Liu W, Yang Z, Zhang Y, Li B, Yuan Y. Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study. Cancer Commun (Lond) 2018;38:26. [PMID: 29784036 DOI: 10.1186/s40880-018-0296-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
339 Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med 2010;2:163-73. [PMID: 24367214 DOI: 10.2147/HMER.S7132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
340 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol. 2013;5:302-310. [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
341 Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 2020;51:102610. [PMID: 31918403 DOI: 10.1016/j.ebiom.2019.102610] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
342 Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12003-12021. [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
343 Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G. RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J 2020;39:e103181. [PMID: 32368828 DOI: 10.15252/embj.2019103181] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 41.0] [Reference Citation Analysis]
344 Lee S, Kang JH, Kim DY, Ahn SH, Park JY, Kim BK, Kim SU, Han KH. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. Hepatol Int. 2017;11:292-299. [PMID: 28324324 DOI: 10.1007/s12072-017-9792-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
345 Chow PK, Poon DY, Khin MW, Singh H, Han HS, Goh AS, Choo SP, Lai HK, Lo RH, Tay KH, Lim TG, Gandhi M, Tan SB, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma. PLoS One 2014;9:e90909. [PMID: 24614178 DOI: 10.1371/journal.pone.0090909] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
346 Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V. VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Res Protoc 2017;6:e17. [PMID: 28202430 DOI: 10.2196/resprot.7016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
347 Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5:178-189. [PMID: 24982766 DOI: 10.3978/j.issn.2078-6891.2014.037] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
348 Khorsandi SE, Heaton N. Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence. Transl Gastroenterol Hepatol 2016;1:25. [PMID: 28138592 DOI: 10.21037/tgh.2016.03.18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
349 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
350 Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol. 2010;2:348-359. [PMID: 21160806 DOI: 10.4251/wjgo.v2.i9.348] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
351 Kim DY, Kim HJ, Han KH, Han SY, Heo J, Woo HY, Um SH, Kim YH, Kweon YO, Lim HY, Yoon JH, Lee WS, Lee BS, Lee HC, Ryoo BY, Yoon SK. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. Cancer Res Treat 2016;48:1243-52. [PMID: 26910470 DOI: 10.4143/crt.2015.278] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
352 Li L, Mo F, Hui EP, Chan SL, Koh J, Tang NLS, Yu SCH, Yeo W. The association of liver function and quality of life of patients with liver cancer. BMC Gastroenterol 2019;19:66. [PMID: 31046687 DOI: 10.1186/s12876-019-0984-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
353 Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol 2019;54:558-70. [PMID: 30788569 DOI: 10.1007/s00535-019-01554-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
354 Yin Y, Sun M, Zhan X, Wu C, Geng P, Sun X, Wu Y, Zhang S, Qin J, Zhuang Z, Liu Y. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC. J Exp Clin Cancer Res 2019;38:83. [PMID: 30770740 DOI: 10.1186/s13046-019-1082-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
355 Cheng CC, Chao WT, Liao CC, Tseng YH, Lai YC, Lai YS, Hsu YH, Liu YH. Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment. Cell Adh Migr 2018;12:19-27. [PMID: 28276928 DOI: 10.1080/19336918.2017.1288789] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
356 Onishi H, Nouso K, Nakamura S, Katsui K, Wada N, Morimoto Y, Miyahara K, Takeuchi Y, Kuwaki K, Yasunaka T. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. Hepatol Int. 2015;9:105-112. [PMID: 25788384 DOI: 10.1007/s12072-014-9592-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
357 Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Nakashima D, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. Cancer Sci 2020;111:3759-69. [PMID: 32716114 DOI: 10.1111/cas.14582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
358 Lin HH, Zhang LL, Yan R, Lu JJ, Hu Y. Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015. Sci Rep 2017;7:12230. [PMID: 28947756 DOI: 10.1038/s41598-017-12061-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
359 Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol. 2013;5:364-371. [PMID: 23898369 DOI: 10.4254/wjh.v5.i7.364] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
360 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4:253-262. [PMID: 26734579 DOI: 10.1159/000367743] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 12.2] [Reference Citation Analysis]
361 Hu HT, Luo JP, Li HL, Guo CY, Yao QJ, Geng X, Jiang L. Transarterial chemoembolization combined with computed tomography-guided 125iodine implantation enhances survival in hepatocellular carcinoma patients with portal vein tumor thrombus. Oncotarget 2017;8:29258-68. [PMID: 28418927 DOI: 10.18632/oncotarget.16491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
362 Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, Krishna Dhali G, Chowdhury A, Schmittgen TD, Kundu GC, Banerjee S. MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis 2017;8:e2706. [PMID: 28358369 DOI: 10.1038/cddis.2017.123] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 17.5] [Reference Citation Analysis]
363 Marinković M, Šprung M, Buljubašić M, Novak I. Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy. Oxid Med Cell Longev 2018;2018:8023821. [PMID: 29643976 DOI: 10.1155/2018/8023821] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 29.7] [Reference Citation Analysis]
364 Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J, Nistor GI, Cao W, Chen C, Dillman RO. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015;111:862-7. [PMID: 25873455 DOI: 10.1002/jso.23897] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
365 Wang SJ, Yang PM. A Bioinformatics Analysis Identifies the Telomerase Inhibitor MST-312 for Treating High-STMN1-Expressing Hepatocellular Carcinoma. J Pers Med 2021;11:332. [PMID: 33922244 DOI: 10.3390/jpm11050332] [Reference Citation Analysis]
366 Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z, Li C, Ren H, Li Y, He X, Shi X, Hui L. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Res 2015;25:477-95. [PMID: 25698578 DOI: 10.1038/cr.2015.23] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
367 Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015;7:1412-20. [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
368 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part I. J Vasc Interv Radiol 2013;24:1157-64. [PMID: 23809510 DOI: 10.1016/j.jvir.2013.04.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
369 Shigekawa Y, Hayami S, Ueno M, Miyamoto A, Suzaki N, Kawai M, Hirono S, Okada KI, Hamamoto R, Yamaue H. Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma. Oncotarget 2018;9:34320-35. [PMID: 30344945 DOI: 10.18632/oncotarget.26144] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
370 Huynh H, Prawira A, Le TBU, Vu TC, Hao HX, Huang A, Wang Y, Porta DG. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Exp Mol Med 2020;52:1857-68. [PMID: 33235319 DOI: 10.1038/s12276-020-00524-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
371 Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 2011;9:120. [PMID: 21787417 DOI: 10.1186/1479-5876-9-120] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
372 Zhou Q, Wong CH, Lau CP, Hui CW, Lui VW, Chan SL, Yeo W. Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. Int J Hepatol 2013;2013:103830. [PMID: 23509629 DOI: 10.1155/2013/103830] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
373 Otsuka T, Nakashita S, Yanagita K, Ario K, Kawasoe H, Kawazoe S, Eguchi Y, Mizuta T. Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Diseases 2015;3:68-77. [PMID: 28943609 DOI: 10.3390/diseases3020068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
374 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
375 Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 2010;12:928-40. [PMID: 21076618 DOI: 10.1593/neo.10804] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
376 Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D, Johnson PJ, Ross PJ. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. Br J Cancer 2013;109:888-90. [PMID: 23880824 DOI: 10.1038/bjc.2013.410] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
377 Parks AL, McWhirter RM, Evason K, Kelley RK. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer 2015;46:161-5. [PMID: 25662892 DOI: 10.1007/s12029-015-9690-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
378 Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S. Linifanib vs Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol. 2015;33:172-179. [PMID: 25488963 DOI: 10.1200/jco.2013.54.3298] [Cited by in Crossref: 320] [Cited by in F6Publishing: 185] [Article Influence: 45.7] [Reference Citation Analysis]
379 Donia M, Hansen SW, Svane IM. Real-world evidence to guide healthcare policies in oncology. Oncotarget 2019;10:4513-5. [PMID: 31360300 DOI: 10.18632/oncotarget.27077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
380 Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget 2015;6:21193-207. [PMID: 26098859 DOI: 10.18632/oncotarget.4176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
381 Yamakado K, Hirota S. Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. World J Gastroenterol 2015;21:10604-8. [PMID: 26457020 DOI: 10.3748/wjg.v21.i37.10604] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
382 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
383 Yau T, Cheng PN, Chan P, Chan W, Chen L, Yuen J, Pang R, Fan ST, Poon RT. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs 2013;31:99-107. [PMID: 22426640 DOI: 10.1007/s10637-012-9807-9] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 7.8] [Reference Citation Analysis]
384 Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011;15:423-41, vii-x. [PMID: 21689622 DOI: 10.1016/j.cld.2011.03.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
385 Kim HY, Park JW. Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and future. Liver Cancer. 2014;3:9-17. [PMID: 24804173 DOI: 10.1159/000343854] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
386 Chen J, Zhou C, Long Y, Yin X. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Tumour Biol 2015;36:183-91. [PMID: 25217986 DOI: 10.1007/s13277-014-2608-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
387 Okusaka T, Otsuka T, Ueno H, Mitsunaga S, Sugimoto R, Muro K, Saito I, Tadayasu Y, Inoue K, Loembé AB, Ikeda M. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Sci 2016;107:1791-9. [PMID: 27627050 DOI: 10.1111/cas.13077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
388 Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545-551. [PMID: 27816492 DOI: 10.1016/j.jhep.2016.10.029] [Cited by in Crossref: 296] [Cited by in F6Publishing: 271] [Article Influence: 59.2] [Reference Citation Analysis]
389 Obi S, Sato T, Sato S, Kanda M, Tokudome Y, Kojima Y, Suzuki Y, Hosoda K, Kawai T, Kondo Y, Isomura Y, Ohyama H, Nakagomi K, Ashizawa H, Miura Y, Amano H, Mochizuki H, Omata M. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int. 2019;13:199-204. [PMID: 30671808 DOI: 10.1007/s12072-019-09929-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
390 Wei PL, Huang CY, Chang YJ. Propyl gallate inhibits hepatocellular carcinoma cell growth through the induction of ROS and the activation of autophagy. PLoS One 2019;14:e0210513. [PMID: 30653551 DOI: 10.1371/journal.pone.0210513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
391 Raoof M, Curley SA. Non-invasive radiofrequency-induced targeted hyperthermia for the treatment of hepatocellular carcinoma. Int J Hepatol 2011;2011:676957. [PMID: 21994866 DOI: 10.4061/2011/676957] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
392 Dai ZJ, Tang W, Lu WF, Gao J, Kang HF, Ma XB, Min WL, Wang XJ, Wu WY. Antiproliferative and apoptotic effects of β-elemene on human hepatoma HepG2 cells. Cancer Cell Int. 2013;13:27. [PMID: 23496852 DOI: 10.1186/1475-2867-13-27] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
393 Hsiao WD, Peng CY, Chuang PH, Lai HC, Cheng KS, Chou JW, Chen YY, Yu CJ, Feng CL, Su WP, Chen SH, Kao JT. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. BMC Gastroenterol 2016;16:50. [PMID: 27117280 DOI: 10.1186/s12876-016-0464-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
394 Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, Zhang YJ, Meng Y, Yang YF, Cong WM, Wu MC, Lau WY, Cheng SQ. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine (Baltimore). 2016;95:e3015. [PMID: 26986115 DOI: 10.1097/md.0000000000003015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 8.2] [Reference Citation Analysis]
395 Jia AY, Popovic A, Mohan AA, Zorzi J, Griffith P, Kim AK, Anders RA, Burkhart RA, Lafaro K, Georgiades C, Azad NS, Liddell RP, Baretti M, Kamel IR, Narang A, Yarchoan M, Meyer J. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control 2021;28:10732748211009945. [PMID: 33882707 DOI: 10.1177/10732748211009945] [Reference Citation Analysis]
396 Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011;34:205-13. [PMID: 21605146 DOI: 10.1111/j.1365-2036.2011.04697.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
397 Hajighasemlou S, Nikbakht M, Pakzad S, Muhammadnejad S, Gharibzadeh S, Mirmoghtadaei M, Zafari F, Seyhoun I, Ai J, Verdi J. Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC. Evid Based Complement Alternat Med 2020;2020:9602728. [PMID: 32617114 DOI: 10.1155/2020/9602728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
398 González R, Rodríguez-Hernández MA, Negrete M, Ranguelova K, Rossin A, Choya-Foces C, Cruz-Ojeda P, Miranda-Vizuete A, Martínez-Ruiz A, Rius-Pérez S, Sastre J, Bárcena JA, Hueber AO, Padilla CA, Muntané J. Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer. Redox Biol 2020;34:101528. [PMID: 32388267 DOI: 10.1016/j.redox.2020.101528] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
399 Kudo M. Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now? Liver Cancer 2015;4:I-VII. [PMID: 26929926 DOI: 10.1159/000367753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
400 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 2015;7:673-687. [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 9.2] [Reference Citation Analysis]
401 Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Clin Gastroenterol Hepatol 2020; 18: 2879-2902. e9. [PMID: 32289533 DOI: 10.1016/j.cgh.2020.04.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
402 Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget. 2016;7:72343-72355. [PMID: 27579537 DOI: 10.18632/oncotarget.11644] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
403 Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers (Basel) 2019;11:E1517. [PMID: 31601010 DOI: 10.3390/cancers11101517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
404 Tsai CN, Yu SC, Lee CW, Pang JS, Wu CH, Lin SE, Chung YH, Tsai CL, Hsieh SY, Yu MC. SOX4 activates CXCL12 in hepatocellular carcinoma cells to modulate endothelial cell migration and angiogenesis in vivo. Oncogene 2020;39:4695-710. [PMID: 32404985 DOI: 10.1038/s41388-020-1319-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
405 Liang R, Zhang J, Liu Z, Liu Z, Li Q, Luo X, Li Y, Ye J, Lin Y. Mechanism and Molecular Network of RBM8A-Mediated Regulation of Oxaliplatin Resistance in Hepatocellular Carcinoma. Front Oncol 2020;10:585452. [PMID: 33552961 DOI: 10.3389/fonc.2020.585452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
406 Fu J, Zhang JY, Wang FS. Tamibarotene: a new hope for therapeutic efficacy in hepatocellular carcinoma patients. Hepatol Int 2014;8:1-3. [PMID: 26202399 DOI: 10.1007/s12072-013-9493-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
407 Ueda H, Fukuchi H, Tanaka C. Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). Oncol Lett. 2012;3:259-263. [PMID: 22740891 DOI: 10.3892/ol.2011.469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
408 Alunni-Fabbroni M, Rönsch K, Huber T, Cyran CC, Seidensticker M, Mayerle J, Pech M, Basu B, Verslype C, Benckert J, Malfertheiner P, Ricke J. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med 2019;17:328. [PMID: 31570105 DOI: 10.1186/s12967-019-2079-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
409 Lee SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Lee J, Yim DS, Lim HY. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest New Drugs. 2012;30:1540-1547. [PMID: 21695438 DOI: 10.1007/s10637-011-9706-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
410 D'Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI. Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 2013;72:869-77. [PMID: 23959464 DOI: 10.1007/s00280-013-2269-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
411 Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. PLoS One. 2013;8:e70010. [PMID: 23922888 DOI: 10.1371/journal.pone.0070010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
412 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2016;22:6851-6863. [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
413 Arai K, Fukumoto T, Kido M, Tanaka M, Kuramitsu K, Kinoshita H, Komatsu S, Tsugawa D, Terai S, Matsumoto T, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis. Surg Today. 2017;47:385-392. [PMID: 27465474 DOI: 10.1007/s00595-016-1384-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
414 Sasaki R, Kanda T, Fujisawa M, Matsumoto N, Masuzaki R, Ogawa M, Matsuoka S, Kuroda K, Moriyama M. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines. Int J Mol Sci 2020;21:E3349. [PMID: 32397371 DOI: 10.3390/ijms21093349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
415 Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Mol Oncol. 2017;11:320-334. [PMID: 28164434 DOI: 10.1002/1878-0261.12039] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
416 Yeh CT, Chen HC, Sung CM, Hsu CL, Lin CC, Pan KT, Tseng JH, Hung CF. Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. BMC Cancer 2011;11:117. [PMID: 21453495 DOI: 10.1186/1471-2407-11-117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
417 Ma Y, Zhang M, Wang J, Huang X, Kuai X, Zhu X, Chen Y, Jia L, Feng Z, Tang Q, Liu Z. High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma. Front Oncol 2019;9:717. [PMID: 31428584 DOI: 10.3389/fonc.2019.00717] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
418 Wu R, Murali R, Kabe Y, French SW, Chiang YM, Liu S, Sher L, Wang CC, Louie S, Tsukamoto H. Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition. Hepatology 2018;68:1726-40. [PMID: 29729190 DOI: 10.1002/hep.30071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
419 Koroki K, Ogasawara S, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer 2020;9:596-612. [PMID: 33083283 DOI: 10.1159/000508809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
420 Sangro B, Maini CL, Ettorre GM, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Sciuto R, Pizzi G, Lastoria S; European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY). Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Eur J Nucl Med Mol Imaging 2018;45:1721-30. [PMID: 29516130 DOI: 10.1007/s00259-018-3968-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
421 Song JE, Kim DY. Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol. 2017;9:808-814. [PMID: 28706579 DOI: 10.4254/wjh.v9.i18.808] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 8.5] [Reference Citation Analysis]
422 Feng M, Pan Y, Kong R, Shu S. Therapy of Primary Liver Cancer. Innovation (N Y) 2020;1:100032. [PMID: 32914142 DOI: 10.1016/j.xinn.2020.100032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
423 Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. BMC Cancer 2020;20:1001. [PMID: 33059615 DOI: 10.1186/s12885-020-07471-3] [Reference Citation Analysis]
424 Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015;15:392. [PMID: 25957784 DOI: 10.1186/s12885-015-1373-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
425 Yang Y, Yuan P, Wei X, Fu C, Li J, Wang W, Wang X, Li Y, Li J. Cultivated and wild Pleurotus ferulae ethanol extracts inhibit hepatocellular carcinoma cell growth via inducing endoplasmic reticulum stress- and mitochondria-dependent apoptosis. Sci Rep 2018;8:13984. [PMID: 30228276 DOI: 10.1038/s41598-018-32225-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
426 Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 2018;23:586-93. [PMID: 29487225 DOI: 10.1634/theoncologist.2017-0479] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
427 Howell J, Pinato DJ, Ramaswami R, Arizumi T, Ferrari C, Gibbin A, Burlone ME, Guaschino G, Toniutto P, Black J. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. Oncotarget. 2017;8:36161-36170. [PMID: 28212535 DOI: 10.18632/oncotarget.15322] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
428 Zhou H, Cai Y, Liu D, Li M, Sha Y, Zhang W, Wang K, Gong J, Tang N, Huang A, Xia J. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma. Cell Prolif 2018;51:e12447. [PMID: 29484736 DOI: 10.1111/cpr.12447] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 11.7] [Reference Citation Analysis]
429 Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017;9:797-807. [PMID: 28706578 DOI: 10.4254/wjh.v9.i18.797] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
430 Katayama K, Imai T, Abe Y, Nawa T, Maeda N, Nakanishi K, Wada H, Fukui K, Ito Y, Yokota I, Ohkawa K. Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis. J Clin Med Res 2018;10:765-71. [PMID: 30214648 DOI: 10.14740/jocmr3559w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
431 Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci. 2013;28:213-219. [PMID: 23400333 DOI: 10.3346/jkms.2013.28.2.213] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
432 Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers (Basel) 2019;11:E1206. [PMID: 31430945 DOI: 10.3390/cancers11081206] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
433 Parsons HM, Chu Q, Karlitz JJ, Stevens JL, Harlan LC. Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States. Liver Cancer 2017;6:216-26. [PMID: 29234628 DOI: 10.1159/000473862] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
434 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
435 Liu Z, Wang Q, Wang X, Xu Z, Wei X, Li J. Circular RNA cIARS regulates ferroptosis in HCC cells through interacting with RNA binding protein ALKBH5. Cell Death Discov 2020;6:72. [PMID: 32802409 DOI: 10.1038/s41420-020-00306-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
436 Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Methodological assessment of HCC literature. Ann Oncol 2013;24 Suppl 2:ii6-14. [PMID: 23715943 DOI: 10.1093/annonc/mdt052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
437 Hou T, Wang T, Mu W, Yang R, Liang S, Zhang Z, Fu S, Gao T, Liu Y, Zhang N. Nanoparticle-Loaded Polarized-Macrophages for Enhanced Tumor Targeting and Cell-Chemotherapy. Nanomicro Lett 2020;13:6. [PMID: 34138195 DOI: 10.1007/s40820-020-00531-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
438 Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer 2010;103:837-44. [PMID: 20717115 DOI: 10.1038/sj.bjc.6605858] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
439 Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020;12:1349-57. [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
440 Finn RS. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer 2012;1:247-56. [PMID: 24159589 DOI: 10.1159/000343839] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
441 Zonca P, Martinek L, Ihnat P, Fleege J. Ectopic liver: different manifestations, one solution. World J Gastroenterol 2013;19:6485-9. [PMID: 24151369 DOI: 10.3748/wjg.v19.i38.6485] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
442 Rau KM, Liu CT, Hsiao YC, Hsiao KY, Wang TM, Hung WS, Su YL, Liu WC, Wang CH, Hsu HL, Chuang PH, Cheng JC, Tseng CP. Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response. J Clin Med. 2020;9. [PMID: 32071283 DOI: 10.3390/jcm9010188] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
443 Greten TF, Lai CW, Li G, Staveley-O'Carroll KF. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology 2019;156:510-24. [PMID: 30287171 DOI: 10.1053/j.gastro.2018.09.051] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 18.3] [Reference Citation Analysis]
444 Yanai S, Nakamura S, Ooho A, Nakamura S, Esaki M, Azuma K, Kitazono T, Matsumoto T. Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment. Clin J Gastroenterol. 2015;8:116-119. [PMID: 25832768 DOI: 10.1007/s12328-015-0566-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
445 Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol. 2014;20:486-497. [PMID: 24574717 DOI: 10.3748/wjg.v20.i2.486] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
446 Yang W, Wang D, Huang L, Chen Y, Wen S, Hong Q, Kang D. Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. Asian Pac J Cancer Prev 2018;19:2043-55. [PMID: 30139041 DOI: 10.22034/APJCP.2018.19.8.2043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
447 Hendrickson PG, Olson M, Luetkens T, Weston S, Han T, Atanackovic D, Fine GC. The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.Oncoimmunology. 2020;9:1673129. [PMID: 32002284 DOI: 10.1080/2162402X.2019.1673129] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
448 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Kanogawa N, Saito T, Motoyama T, Tawada A, Kanai F, Yokosuka O. Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. Invest New Drugs. 2016;34:255-260. [PMID: 26769245 DOI: 10.1007/s10637-016-0323-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
449 Oh CR, Kong SY, Im HS, Kim HJ, Kim MK, Yoon KA, Cho EH, Jang JH, Lee J, Kang J, Park SR, Ryoo BY. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. BMC Cancer 2019;19:292. [PMID: 30935424 DOI: 10.1186/s12885-019-5483-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
450 Kung-Chun Chiu D, Pui-Wah Tse A, Law CT, Ming-Jing Xu I, Lee D, Chen M, Kit-Ho Lai R, Wai-Hin Yuen V, Wing-Sum Cheu J, Wai-Hung Ho D, Wong CM, Zhang H, Oi-Lin Ng I, Chak-Lui Wong C. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. Cell Death Dis 2019;10:934. [PMID: 31819034 DOI: 10.1038/s41419-019-2155-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 13.5] [Reference Citation Analysis]
451 Ali R, Gabr A, Abouchaleh N, Al Asadi A, Mora RA, Kulik L, Abecassis M, Riaz A, Salem R, Lewandowski RJ. Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases. Cardiovasc Intervent Radiol 2018;41:260-9. [DOI: 10.1007/s00270-017-1791-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
452 Chan KM, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Lee WC. Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. Cancer Manag Res 2019;11:1013-21. [PMID: 30774429 DOI: 10.2147/CMAR.S186678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
453 Girardi DM, Pacífico JPM, Guedes de Amorim FPL, Dos Santos Fernandes G, Teixeira MC, Pereira AAL. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals (Basel) 2020;14:28. [PMID: 33396181 DOI: 10.3390/ph14010028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
454 Lin WR, Hsu CW, Chen YC, Chang ML, Liang KH, Huang YH, Yeh CT. GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. Mol Clin Oncol 2014;2:630-40. [PMID: 24940508 DOI: 10.3892/mco.2014.294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
455 Brunetti O, Gnoni A, Licchetta A, Longo V, Calabrese A, Argentiero A, Delcuratolo S, Solimando AG, Casadei-Gardini A, Silvestris N. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Kaunas) 2019;55:E707. [PMID: 31640191 DOI: 10.3390/medicina55100707] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
456 Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125-137. [PMID: 30600478 DOI: 10.1007/s12072-018-9919-1] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 42.5] [Reference Citation Analysis]
457 Yang PM, Lin LS, Liu TP. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules 2020;10:E117. [PMID: 31936661 DOI: 10.3390/biom10010117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
458 Pan F, Lin XR, Hao LP, Chu XY, Wan HJ, Wang R. The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives. Front Cell Dev Biol 2021;9:674919. [PMID: 34046411 DOI: 10.3389/fcell.2021.674919] [Reference Citation Analysis]
459 He S, Jiang W, Fan K, Wang X. The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:626984. [PMID: 33833987 DOI: 10.3389/fonc.2021.626984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
460 Yao S, Johnson C, Hu Q, Yan L, Liu B, Ambrosone CB, Wang J, Liu S. Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations. Oncotarget. 2016;7:40491-40499. [PMID: 27246981 DOI: 10.18632/oncotarget.9636] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
461 Aihara Y, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Morioka C, Kaji K, Tastumi H, Nakanishi K, Nakamura M, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Uemura M, Fukui H. A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2012;4:115-8. [PMID: 22645635 DOI: 10.4251/wjgo.v4.i5.115] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
462 Zhu H, Zhao Y, Wang X. The radiosensitive effect of apatinib for hepatocellular carcinoma patient with big paraspinal metastasis: A case report. Medicine (Baltimore) 2018;97:e9598. [PMID: 29480860 DOI: 10.1097/MD.0000000000009598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
463 Rong LW, Wang RX, Zheng XL, Feng XQ, Zhang L, Zhang L, Lin Y, Li ZP, Wang X. Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition. Oncol Lett 2017;13:5028-34. [PMID: 28599504 DOI: 10.3892/ol.2017.6059] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
464 Kudo M. A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. Liver Cancer 2020;9:367-77. [PMID: 32999864 DOI: 10.1159/000507934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
465 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
466 He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5:953-960. [PMID: 31070690 DOI: 10.1001/jamaoncol.2019.0250] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 62.0] [Reference Citation Analysis]
467 Salimon M, Prieux-Klotz C, Tougeron D, Hautefeuille V, Caulet M, Gournay J, Matysiak-Budnik T, Bennouna J, Tiako Meyo M, Lecomte T, Zaanan A, Touchefeu Y. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer. 2018;118:325-330. [PMID: 29169182 DOI: 10.1038/bjc.2017.413] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
468 Li H, Qin S, Liu Y, Chen Z, Ren Z, Xiong J, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Des Devel Ther 2021;15:1873-82. [PMID: 33976538 DOI: 10.2147/DDDT.S304857] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
469 Perboni G, Costa P, Fibbia GC, Morandini B, Scalzini A, Tagliani A, Cengarle R, Aitini E. Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report. Oncologist. 2010;15:142-145. [PMID: 20142333 DOI: 10.1634/theoncologist.2010-0010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
470 Lin Z, Xia S, Liang Y, Ji L, Pan Y, Jiang S, Wan Z, Tao L, Chen J, Lin C, Liang X, Xu J, Cai X. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription. Theranostics 2020;10:8834-50. [PMID: 32754282 DOI: 10.7150/thno.45158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
471 Spratlin JL, Chu Q, Koski S, King K, Mulder K. Targeting metastatic upper gastrointestinal adenocarcinomas. World J Clin Oncol 2011;2:135-49. [PMID: 21611088 DOI: 10.5306/wjco.v2.i3.135] [Cited by in CrossRef: 2] [Article Influence: 0.2] [Reference Citation Analysis]
472 Li MX, Zhao H, Bi XY, Li ZY, Yao XS, Li H, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao DB, Cai JQ. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. Oncotarget 2016;7:86630-47. [PMID: 27880930 DOI: 10.18632/oncotarget.13428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
473 Zhang B, Shan H, Li D, Li ZR, Zhu KS, Jiang ZB. The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma. Cancer Biol Ther 2012;13:1175-84. [PMID: 22922789 DOI: 10.4161/cbt.21347] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
474 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
475 He M, Hou J, Wang L, Zheng M, Fang T, Wang X, Xia J. Actinidia chinensis Planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9. Oncotarget 2017;8:42136-48. [PMID: 28178673 DOI: 10.18632/oncotarget.15010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
476 Gong XL, Qin SK. Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 2016;22:6582-6594. [PMID: 27547002 DOI: 10.3748/wjg.v22.i29.6582] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
477 Yan SY, Zhang Y, Sun C, Cao HX, Li GM, Wang YQ, Fan JG. The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. Oncol Lett 2016;12:951-5. [PMID: 27446375 DOI: 10.3892/ol.2016.4694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
478 Forner A, Rodríguez-Lopez C, Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:183-5. [PMID: 31186883 DOI: 10.1002/cld.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
479 Li X, Wan J, Wu Z, Tu J, Hu Y, Wu S, Lou L. Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018;12:3043-9. [PMID: 30271119 DOI: 10.2147/DDDT.S151241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
480 Jiang N, Zhang X, Qin D, Yang J, Wu A, Wang L, Sun Y, Li H, Shen X, Lin J, Kantawong F, Wu J. Identification of Core Genes Related to Progression and Prognosis of Hepatocellular Carcinoma and Small-Molecule Drug Predication. Front Genet 2021;12:608017. [PMID: 33708237 DOI: 10.3389/fgene.2021.608017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
481 Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti O, Cardellino GG, Frassineti GL, Scartozzi M. Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. Oncotarget 2017;8:66699-708. [PMID: 29029548 DOI: 10.18632/oncotarget.19449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
482 Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, Pelizzaro F, Marra F, Trevisani F, Giannini EG. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. J Clin Med 2021;10:3201. [PMID: 34361985 DOI: 10.3390/jcm10153201] [Reference Citation Analysis]
483 Freimark BD, Gong J, Ye D, Gray MJ, Nguyen V, Yin S, Hatch MM, Hughes CC, Schroit AJ, Hutchins JT, Brekken RA, Huang X. Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. Cancer Immunol Res 2016;4:531-40. [PMID: 27045021 DOI: 10.1158/2326-6066.CIR-15-0250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
484 Orsi G, Tovoli F, Dadduzio V, Vivaldi C, Brunetti O, Ielasi L, Conti F, Rovesti G, Gramantieri L, Rizzato MD, Pecora I, Argentiero A, Teglia F, Lonardi S, Salani F, Granito A, Zagonel V, Marisi G, Cabibbo G, Foschi FG, Benevento F, Cucchetti A, Piscaglia F, Cascinu S, Scartozzi M, Casadei-Gardini A. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Target Oncol 2020;15:773-85. [PMID: 33044683 DOI: 10.1007/s11523-020-00757-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
485 Murakami Y, Kenjo M, Ishikawa K, Sakayauchi T, Itasaka S, Negoro Y, Jingu K, Nishimura Y, Nagata Y, Ogawa K. Risk factors for severe gastrointestinal toxicity in patients receiving palliative radiotherapy for metastatic bone tumors: association with the use of molecular-targeted agents. J Radiat Res 2020;61:629-34. [PMID: 32567666 DOI: 10.1093/jrr/rraa035] [Reference Citation Analysis]
486 Song A, Eo W, Kim S, Shim B, Lee S. Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study. BMC Complement Altern Med 2018;18:176. [PMID: 29879960 DOI: 10.1186/s12906-018-2240-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
487 Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare. Pharmacoeconomics 2014;32:63-74. [PMID: 24293197 DOI: 10.1007/s40273-013-0109-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
488 Li XP, Jing W, Sun JJ, Liu ZY, Zhang JT, Sun W, Zhu W, Fan YZ. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo. BMC Cancer 2015;15:527. [PMID: 26187792 DOI: 10.1186/s12885-015-1521-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
489 Feng YM, Feng CW, Lu CL, Lee MY, Chen CY, Chen SC. Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients. Jpn J Clin Oncol 2015;45:336-42. [PMID: 25646358 DOI: 10.1093/jjco/hyv007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
490 Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 2011;16:1508-19. [PMID: 22016478 DOI: 10.1634/theoncologist.2011-0115] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
491 Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, Bae SH, Kim do Y, Heo J, Kim YJ. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS One. 2016;11:e0154986. [PMID: 27149067 DOI: 10.1371/journal.pone.0154986] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
492 Kong M, Hong SE, Choi WS, Choi J, Kim Y. Treatment outcomes of helical intensity-modulated radiotherapy for unresectable hepatocellular carcinoma. Gut Liver. 2013;7:343-351. [PMID: 23710317 DOI: 10.5009/gnl.2013.7.3.343] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
493 Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Nomura T, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Ishihara A, Deguchi A, Arai H, Shimose S, Shirono T, Nakano M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Aino H, Matsukuma N, Matsugaki S, Ogata K, Yano Y, Ueno T, Kajiwara M, Itano S, Fukuizumi K, Kawano H, Noguchi K, Tanaka M, Yamaguchi T, Kuromatsu R, Kawaguchi A, Koga H, Torimura T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan. Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers (Basel) 2021;13:646. [PMID: 33562793 DOI: 10.3390/cancers13040646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
494 Rouleau L, Antony AN, Bisetto S, Newberg A, Doria C, Levine M, Monti DA, Hoek JB. Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity. Free Radic Biol Med 2016;95:308-22. [PMID: 27036367 DOI: 10.1016/j.freeradbiomed.2016.03.031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
495 Takada H, Kurosaki M, Tsuchiya K, Komiyama Y, Itakura J, Takahashi Y, Nakanishi H, Yasui Y, Tamaki N, Maeyashiki C, Kaneko S, Takaura K, Higuchi M, Okada M, Wang W, Osawa L, Sekiguchi S, Hayakawa Y, Yamashita K, Enomoto N, Izumi N. Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31461985 DOI: 10.3390/cancers11091256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
496 Feng J, Dai W, Mao Y, Wu L, Li J, Chen K, Yu Q, Kong R, Li S, Zhang J, Ji J, Wu J, Mo W, Xu X, Guo C. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Cancer Res 2020;39:24. [PMID: 32000827 DOI: 10.1186/s13046-020-1528-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 22.0] [Reference Citation Analysis]
497 Zhang HL, Qin XJ, Wang HK, Gu WJ, Ma CG, Shi GH, Zhou LP, Ye DW. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget 2015;6:36870-83. [PMID: 26472104 DOI: 10.18632/oncotarget.4874] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
498 Zhou B, Lu Q, Liu J, Fan L, Wang Y, Wei W, Wang H, Sun G. Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway. Int J Biol Sci 2019;15:1905-20. [PMID: 31523192 DOI: 10.7150/ijbs.32550] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
499 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019;25:3704-3721. [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 37.0] [Reference Citation Analysis]
500 Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, Sumino Y. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. World J Gastroenterol. 2012;18:5753-5758. [PMID: 23155317 DOI: 10.3748/wjg.v18.i40.5753] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
501 Shao W, Zhang F, Cong N, Li J, Song J. Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma. Oncol Lett 2014;8:2263-6. [PMID: 25289106 DOI: 10.3892/ol.2014.2512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
502 Raoul JL, Adhoute X, Gilabert M, Edeline J. How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World J Hepatol. 2016;8:1541-1546. [PMID: 28050234 DOI: 10.4254/wjh.v8.i35.1541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
503 Hung HC, Lee JC, Wang YC, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Chan KM, Lee WC. Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1607. [PMID: 33807219 DOI: 10.3390/cancers13071607] [Reference Citation Analysis]
504 Azizi AA, Hadjinicolaou AV, Goncalves C, Duckworth A, Basu B. Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. Front Oncol 2020;10:570958. [PMID: 33102226 DOI: 10.3389/fonc.2020.570958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020;69:1492-501. [PMID: 31801872 DOI: 10.1136/gutjnl-2019-318934] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 31.0] [Reference Citation Analysis]
506 Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021;27:2415-33. [PMID: 34040331 DOI: 10.3748/wjg.v27.i19.2415] [Reference Citation Analysis]
507 Ye M, Xu M, Ding M, Ji C, Ji J, Ji F, Wei W, Yang S, Zhou B. Gender associated effects of the ethanolic extracts of Chinese propolis on the hepatic transcriptome in ethanol-treated mice. Iran J Basic Med Sci 2019;22:1211-7. [PMID: 31998465 DOI: 10.22038/ijbms.2019.37348.8886] [Reference Citation Analysis]
508 Zhang W. Sorafenib in adjuvant setting: call for precise and personalized therapy. Transl Gastroenterol Hepatol 2016;1:13. [PMID: 28138580 DOI: 10.21037/tgh.2016.03.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
509 Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC). Clin Transl Oncol 2012;14:564-74. [PMID: 22855137 DOI: 10.1007/s12094-012-0842-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
510 Kempinska K, Malik B, Borkin D, Klossowski S, Shukla S, Miao H, Wang J, Cierpicki T, Grembecka J. Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma. Mol Cancer Ther 2018;17:26-38. [PMID: 29142068 DOI: 10.1158/1535-7163.MCT-17-0580] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
511 Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, Poon RT. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011;16:1270-1279. [PMID: 21885876 DOI: 10.1634/theoncologist.2011-0105] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 7.0] [Reference Citation Analysis]
512 Kudo M. Biomarkers and Personalized Sorafenib Therapy. Liver Cancer 2014;3:399-404. [PMID: 26280001 DOI: 10.1159/000343870] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
513 Fang Q, Chen H. Development of a Novel Autophagy-Related Prognostic Signature and Nomogram for Hepatocellular Carcinoma. Front Oncol 2020;10:591356. [PMID: 33392087 DOI: 10.3389/fonc.2020.591356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
514 Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Masaki K, Waki K, Kohno H, Kohno H, Moriya T, Nagaoki Y, Tamura T, Amano H, Katamura Y, Chayama K. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer 2018;18:633. [PMID: 29866075 DOI: 10.1186/s12885-018-4519-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
515 Wang X, Ding J, Feng Y, Weng L, Zhao G, Xiang J, Zhang M, Xing D. Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides. Oncol Lett 2017;13:1509-17. [PMID: 28454283 DOI: 10.3892/ol.2017.5602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
516 Tsai CL, Hsu FM, Cheng JC. How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer. 2016;5:210-220. [PMID: 27493896 DOI: 10.1159/000367767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
517 Yin F, Feng F, Wang L, Wang X, Li Z, Cao Y. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis 2019;10:672. [PMID: 31511501 DOI: 10.1038/s41419-019-1884-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
518 Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166. [PMID: 25752327 DOI: 10.1111/liv.12818] [Cited by in Crossref: 369] [Cited by in F6Publishing: 343] [Article Influence: 61.5] [Reference Citation Analysis]
519 Labeur TA, van Vugt JLA, Ten Cate DWG, Takkenberg RB, IJzermans JNM, Groot Koerkamp B, de Man RA, van Delden OM, Eskens FALM, Klümpen HJ. Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Liver Cancer 2019;8:255-70. [PMID: 31602369 DOI: 10.1159/000493586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
520 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016;8:703-15. [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
521 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 229] [Article Influence: 83.6] [Reference Citation Analysis]
522 Chen J, Huang J, Chen M, Yang K, Chen J, Wang J, Xu L, Zhou Z, Zhang Y. Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 patients. J Cancer 2017;8:2984-91. [PMID: 28928890 DOI: 10.7150/jca.20978] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
523 Belum VR, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, Busam KJ, Gerber PA, Lacouture ME. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 2015;26:2496-502. [PMID: 26387145 DOI: 10.1093/annonc/mdv390] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
524 Liu F, Meng Z, Shao G, Wang J, Wang Z, Yang J, Yip CS, He D. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. Mol Biol Rep 2017;44:149-58. [PMID: 27981445 DOI: 10.1007/s11033-016-4092-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
525 Thompson SM, Callstrom MR, Knudsen BE, Anderson JL, Sutor SL, Butters KA, Kuo C, Grande JP, Roberts LR, Woodrum DA. Molecular bioluminescence imaging as a noninvasive tool for monitoring tumor growth and therapeutic response to MRI-guided laser ablation in a rat model of hepatocellular carcinoma. Invest Radiol 2013;48:413-21. [PMID: 23262791 DOI: 10.1097/RLI.0b013e31827a4a3f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
526 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 7.4] [Reference Citation Analysis]
527 Liang RB, Zhao Y, He MK, Wen DS, Bu XY, Huang YX, Lai ZC, Xu YJ, Kan A, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M. Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:619461. [PMID: 34055599 DOI: 10.3389/fonc.2021.619461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
528 Saber S, Mahmoud A, Helal N, El-Ahwany E, Abdelghany R. Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice. Open Access Maced J Med Sci. 2018;6:955-960. [PMID: 29983784 DOI: 10.3889/oamjms.2018.167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
529 Zhang L, Yan ZP, Hou ZH, Huang P, Yang MJ, Zhang S, Zhang S, Zhang SH, Zhu XL, Ni CF, Li Q. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib. Front Mol Biosci 2021;8:624366. [PMID: 34124139 DOI: 10.3389/fmolb.2021.624366] [Reference Citation Analysis]
530 Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci 2019;76:4203-19. [PMID: 31300868 DOI: 10.1007/s00018-019-03215-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
531 Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013;119:3334-42. [PMID: 23821538 DOI: 10.1002/cncr.28209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
532 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 104] [Article Influence: 11.7] [Reference Citation Analysis]
533 Kim H, Yu SJ, Yeo I, Cho YY, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Lee S, Jun J, Park T, Yoon JH, Kim Y. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). Mol Cell Proteomics 2017;16:1312-23. [PMID: 28550167 DOI: 10.1074/mcp.M116.066704] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 3.8] [Reference Citation Analysis]
534 Lee JJX, Chan JJ, Choo SP. Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases 2015;3:306-24. [PMID: 28943627 DOI: 10.3390/diseases3040306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
535 Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therap Adv Gastroenterol 2018;11:1756284818808086. [PMID: 30377451 DOI: 10.1177/1756284818808086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
536 Matsukuma S, Eguchi H, Wada H, Noda T, Shindo Y, Tokumitsu Y, Matsui H, Takahashi H, Kobayashi S, Nagano H. Liver resection with thrombectomy for patients with hepatocellular carcinoma and tumour thrombus in the inferior vena cava or right atrium. BJS Open 2020;4:241-51. [PMID: 32012492 DOI: 10.1002/bjs5.50258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
537 Kajihara J, Tomimaru Y, Eguchi H, Yamada D, Wada H, Tomokuni A, Asaoka T, Kawamoto K, Marubashi S, Nagano H, Umeshita K, Doki Y, Mori M. The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma. Dig Dis Sci 2016;61:1572-81. [PMID: 26725068 DOI: 10.1007/s10620-015-4018-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
538 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
539 She WH, Cheung TT. Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Transl Gastroenterol Hepatol. 2016;1:34. [PMID: 28138601 DOI: 10.21037/tgh.2016.03.04] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
540 Amicone L, Marchetti A. Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:24. [PMID: 29971255 DOI: 10.21037/tgh.2018.04.05] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
541 Zeng J, Wang C, Wang Y, Luo Z, Zhang Y, Luo X. Sorafenib plus partial splenic embolism for treatment of hepatocellular carcinoma Barcelona stage C combined with hypersplenism: a case series. J Int Med Res 2021;49:3000605211023351. [PMID: 34139869 DOI: 10.1177/03000605211023351] [Reference Citation Analysis]
542 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 100] [Cited by in F6Publishing: 70] [Article Influence: 100.0] [Reference Citation Analysis]
543 Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist 2016;21:1113-20. [PMID: 27185615 DOI: 10.1634/theoncologist.2015-0478] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 12.8] [Reference Citation Analysis]
544 Colombo GL, Cammà C, Attili AF, Ganga R, Gaeta GB, Brancaccio G, Franzini JM, Volpe M, Turchetti G. Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag 2015;11:1603-12. [PMID: 26527877 DOI: 10.2147/TCRM.S88208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
545 Tsai TH, Chen YJ, Wang LY, Hsieh CH. Impact of Local Liver Irradiation Concurrent Versus Sequential with Lenvatinib on Pharmacokinetics and Biodistribution. Cancers (Basel) 2021;13:1598. [PMID: 33808407 DOI: 10.3390/cancers13071598] [Reference Citation Analysis]
546 Lee S, Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. J Hepatocell Carcinoma 2015;2:39-47. [PMID: 27508193 DOI: 10.2147/JHC.S79353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
547 Riaño I, Martín L, Varela M, Serrano T, Núñez O, Mínguez B, Rodrigues PM, Perugorria MJ, Banales JM, Arenas JI. Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). Cancers (Basel) 2020;12:E1900. [PMID: 32674461 DOI: 10.3390/cancers12071900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
548 Likhitsup A, Razumilava N, Parikh ND. Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future. Clin Liver Dis (Hoboken) 2019;13:13-9. [PMID: 31168360 DOI: 10.1002/cld.782] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
549 Qiu Z, Shen L, Chen S, Qi H, Cao F, Xie L, Fan W. Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma:A Propensity Score Matching Analysis. Cancer Manag Res 2019;11:9321-30. [PMID: 31802950 DOI: 10.2147/CMAR.S223271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
550 Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett 2015;9:527-34. [PMID: 25624883 DOI: 10.3892/ol.2014.2727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
551 Nakanishi H, Kurosaki M, Tsuchiya K, Yasui Y, Higuchi M, Yoshida T, Komiyama Y, Takaura K, Hayashi T, Kuwabara K, Nakakuki N, Takada H, Ueda M, Tamaki N, Suzuki S, Itakura J, Takahashi Y, Izumi N. Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer 2016;5:257-68. [PMID: 27781198 DOI: 10.1159/000449337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
552 Le VQ, Nguyen VH, Nguyen VH, Nguyen TL, Sudenga SL, Trinh LH, Nguyen VT, Nguyen TTH. Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam. Cancer Control 2019;26:1073274819862793. [PMID: 31290350 DOI: 10.1177/1073274819862793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
553 Haruna Y, Yakushijin T, Kawamoto S. Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study. Cancer Med 2021;10:914-22. [PMID: 33481328 DOI: 10.1002/cam4.3674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
554 Coleman EL, Olamiju B, Leventhal JS. Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review). Oncol Rep 2021;45:891-8. [PMID: 33650659 DOI: 10.3892/or.2020.7911] [Reference Citation Analysis]
555 Sano S, Nakata S, Wada S, Kuroiwa M, Sakai H, Kusama K, Machida T, Nishio A, Ito I, Sodeyama H. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report. World J Surg Oncol 2019;17:229. [PMID: 31878937 DOI: 10.1186/s12957-019-1772-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
556 Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia. 2013;15:1161-1171. [PMID: 24204195 DOI: 10.1593/neo.13812] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
557 Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020;12:663-76. [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
558 Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol. 2015;21:5445-5453. [PMID: 25987766 DOI: 10.3748/wjg.v21.i18.5445] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
559 Ye L, Yang X, Guo E, Chen W, Lu L, Wang Y, Peng X, Yan T, Zhou F, Liu Z. Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. PLoS One 2014;9:e96664. [PMID: 24797816 DOI: 10.1371/journal.pone.0096664] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
560 Yoo C, Park JW, Kim YJ, Kim DY, Yu SJ, Lim TS, Lee SJ, Ryoo BY, Lim HY. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Invest New Drugs. 2019;37:567-572. [PMID: 30523474 DOI: 10.1007/s10637-018-0707-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
561 Cheng Z, He L, Guo Y, Song Y, Song S, Zhang L. The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis. World J Surg Oncol 2020;18:243. [PMID: 32917226 DOI: 10.1186/s12957-020-02017-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
562 Kotani K, Enomoto M, Okada M, Yoshida K, Motoyama H, Fujii H, Hagihara A, Uchida-Kobayashi S, Morikawa H, Murakami Y, Tamori A, Kawada N. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma. Clin J Gastroenterol 2019;12:355-60. [PMID: 31020569 DOI: 10.1007/s12328-019-00983-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
563 Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 2013;6:511-9. [PMID: 24151531 DOI: 10.1593/tlo.13481] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
564 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
565 Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma. Strahlenther Onkol 2019;195:254-64. [PMID: 30413833 DOI: 10.1007/s00066-018-1391-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
566 Oh MJ, Lee HJ, Lee SH. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. Clin Mol Hepatol. 2013;19:288-299. [PMID: 24133667 DOI: 10.3350/cmh.2013.19.3.288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
567 Mußbach F, Ungefroren H, Günther B, Katenkamp K, Henklein P, Westermann M, Settmacher U, Lenk L, Sebens S, Müller JP, Böhmer FD, Kaufmann R. Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer 2016;15:54. [PMID: 27473374 DOI: 10.1186/s12943-016-0538-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
568 Jiang SS, Tang Y, Zhang YJ, Weng DS, Zhou ZG, Pan K, Pan QZ, Wang QJ, Liu Q, He J, Zhao JJ, Li J, Chen MS, Chang AE, Li Q, Xia JC. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget. 2015;6:41339-41349. [PMID: 26515587 DOI: 10.18632/oncotarget.5463] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
569 Ahn SJ, Park MS, Kim KA, Park JY, Kim I, Kang WJ, Lee SK, Kim MJ. 18F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One. 2013;8:e71571. [PMID: 23940769 DOI: 10.1371/journal.pone.0071571] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
570 Ochi M, Kamoshida T, Ohkawara A, Ohkawara H, Kakinoki N, Hirai S, Yanaka A. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.World J Gastroenterol. 2018;24:3155-3162. [PMID: 30065561 DOI: 10.3748/wjg.v24.i28.3155] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
571 Lu L, Sun HC, Zhang W, Chai ZT, Zhu XD, Kong LQ, Wang WQ, Zhang KZ, Zhang YY, Zhang QB, Ao JY, Li JQ, Wang L, Wu WZ, Tang ZY. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. PLoS One 2013;8:e65023. [PMID: 23741443 DOI: 10.1371/journal.pone.0065023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
572 Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, Kudo M, Noguchi M. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients. J Immunol Res 2015;2015:473909. [PMID: 26539554 DOI: 10.1155/2015/473909] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
573 Kao JT, Feng CL, Yu CJ, Tsai SM, Hsu PN, Chen YL, Wu YY. IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. BMC Gastroenterol 2015;15:50. [PMID: 25908103 DOI: 10.1186/s12876-015-0283-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
574 Lee DY, Park JW, Kim TH, Lee JH, Kim BH, Woo SM, Kim SS, Lee WJ, Kim DY, Kim CM. Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma. Strahlenther Onkol 2015;191:835-44. [PMID: 26174506 DOI: 10.1007/s00066-015-0873-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
575 Kitajima T, Hatano E, Mitsunori Y, Taura K, Fujimoto Y, Mizumoto M, Okajima H, Kaido T, Minamiguchi S, Uemoto S. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clin J Gastroenterol. 2015;8:300-305. [PMID: 26249525 DOI: 10.1007/s12328-015-0594-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
576 Ohki T, Kondo M, Karasawa Y, Kawamura S, Maeshima S, Kojima K, Seki M, Toda N, Shioda Y, Tagawa K. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Adv Ther 2017;34:1097-108. [PMID: 28389996 DOI: 10.1007/s12325-017-0524-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
577 Jeong KY, Lee EJ, Yang SH, Seong J. Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma. J Radiat Res 2015;56:37-45. [PMID: 25225286 DOI: 10.1093/jrr/rru077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
578 Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J. Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial. Liver Cancer 2021;10:249-59. [PMID: 34239811 DOI: 10.1159/000514420] [Reference Citation Analysis]
579 DU J, Qian X, Liu B. Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature. Oncol Lett 2013;5:381-5. [PMID: 23255954 DOI: 10.3892/ol.2012.974] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
580 Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. Exp Mol Med 2018;50:1-9. [PMID: 30315182 DOI: 10.1038/s12276-018-0159-1] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 30.0] [Reference Citation Analysis]
581 Granito A, Marinelli S, Negrini G, Menetti S, Benevento F, Bolondi L. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol 2016;9:240-9. [PMID: 26929785 DOI: 10.1177/1756283X15618129] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 8.6] [Reference Citation Analysis]
582 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
583 Liu CY, Chang HS, Chen IS, Chen CJ, Hsu ML, Fu SL, Chen YJ. Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells. Radiat Oncol. 2011;6:56. [PMID: 21624128 DOI: 10.1186/1748-717x-6-56] [Cited by in Crossref: 39] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
584 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020;26:1888-900. [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
585 Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB. JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol 2020;7:HEP18. [PMID: 32273976 DOI: 10.2217/hep-2020-0001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
586 Young S, Taylor AJ, Sanghvi T. Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. J Clin Transl Hepatol 2018;6:189-97. [PMID: 29951364 DOI: 10.14218/JCTH.2017.00059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 3.7] [Reference Citation Analysis]
587 Sommer CM, Stampfl U, Kauczor HU, Pereira PL. [National S3 guidelines on hepatocellular carcinoma]. Radiologe 2014;54:642-53. [PMID: 25047521 DOI: 10.1007/s00117-014-2656-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
588 Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29:3960-7. [PMID: 21911714 DOI: 10.1200/JCO.2011.37.1021] [Cited by in Crossref: 196] [Cited by in F6Publishing: 117] [Article Influence: 19.6] [Reference Citation Analysis]
589 Faivre S, de Gramont A, Raymond E. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib? Target Oncol 2016;11:565-7. [PMID: 26996978 DOI: 10.1007/s11523-016-0427-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
590 Park HC, Yu JI, Cheng JC, Zeng ZC, Hong JH, Wang ML, Kim MS, Chi KH, Liang PC, Lee RC, Lau WY, Han KH, Chow PK, Seong J. Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer. 2016;5:162-174. [PMID: 27493892 DOI: 10.1159/000367766] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
591 Huang S, Li D, Zhuang L, Sun L, Wu J. A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World J Surg Oncol 2021;19:168. [PMID: 34112190 DOI: 10.1186/s12957-021-02280-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
592 Liu C, Xing W, Si T, Yu H, Guo Z. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget 2017;8:100734-45. [PMID: 29246017 DOI: 10.18632/oncotarget.20140] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
593 Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V, Pan H, Yau T, Guo Y, Chen M, Ren Z, Xu J, Yen CJ, Lin ZZ, Manenti L, Gu Y, Sun Y, Tiedt R, Hao L, Song W, Tanwandee T. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919889001. [PMID: 31853265 DOI: 10.1177/1758835919889001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
594 Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, Shiina S, Fontana A, Torzilli G. Hepatocellular Carcinoma: The Role of Interventional Oncology. Liver Cancer. 2016;6:34-43. [PMID: 27995086 DOI: 10.1159/000449346] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
595 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-012-0233-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
596 Saeki I, Yamasaki T, Maeda M, Kawano R, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer 2018;7:359-71. [PMID: 30488024 DOI: 10.1159/000487858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
597 Zhu AX. Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)? BMC Med 2009;7:42. [PMID: 19703270 DOI: 10.1186/1741-7015-7-42] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
598 Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol. 2012;18:1933-1939. [PMID: 22563174 DOI: 10.3748/wjg.v18.i16.1933] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
599 Cho J, Lee J, Kim J, Kim ST, Lee S, Kim SY, Ha SY, Park CK, Lim HY. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Transl Oncol 2016;9:466-71. [PMID: 27751352 DOI: 10.1016/j.tranon.2016.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
600 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 14.5] [Reference Citation Analysis]
601 Peng SY, Wang XA, Huang CY, Li JT, Hong DF, Wang YF, Xu B. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2018;24:4527-35. [PMID: 30386102 DOI: 10.3748/wjg.v24.i40.4527] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
602 Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit. 2011;17:RA169-RA176. [PMID: 21804474 DOI: 10.12659/msm.881892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
603 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 123] [Article Influence: 4.3] [Reference Citation Analysis]
604 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Reference Citation Analysis]
605 Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Kikukawa C, Suehiro Y, Yamaoka K, Ando Y, Uchikawa S, Morio K, Nakahara T, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer 2021;10:151-60. [PMID: 33977091 DOI: 10.1159/000513706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
606 Cheon J, Chon HJ, Bang Y, Park NH, Shin JW, Kim KM, Lee HC, Lee J, Yoo C, Ryoo BY. Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. Liver Cancer 2020;9:613-24. [PMID: 33083284 DOI: 10.1159/000508901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
607 Zhang YF, Wei W, Wang JH, Xu L, Jian PE, Xiao CZ, Zhong XP, Shi M, Guo RP. Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Onco Targets Ther 2016;9:4239-46. [PMID: 27471398 DOI: 10.2147/OTT.S106659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
608 Raoul JL, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, Bourlière M. Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer 2019;8:457-67. [PMID: 31799203 DOI: 10.1159/000497161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
609 Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020;6:e204930. [PMID: 33090186 DOI: 10.1001/jamaoncol.2020.4930] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
610 Khan N, Maurya S, Bammidi S, Jayandharan GR. AAV6 Vexosomes Mediate Robust Suicide Gene Delivery in a Murine Model of Hepatocellular Carcinoma. Mol Ther Methods Clin Dev 2020;17:497-504. [PMID: 32258213 DOI: 10.1016/j.omtm.2020.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
611 Chien SC, Chen CY, Cheng PN, Liu YS, Cheng HC, Chuang CH, Chang TT, Chiu HC, Lin YJ, Chiu YC. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer 2019;8:186-202. [PMID: 31192155 DOI: 10.1159/000489790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
612 Kok VC, Chen YC, Chen YY, Su YC, Ku MC, Kuo JT, Yoshida GJ. Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study. Cancers (Basel). 2019;11. [PMID: 31311148 DOI: 10.3390/cancers11070985] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
613 Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RTP, Bottaro DP. A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2017;23:2405-13. [PMID: 27821605 DOI: 10.1158/1078-0432.CCR-16-1789] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
614 Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib. Eur Radiol 2021;31:1608-19. [PMID: 32827266 DOI: 10.1007/s00330-020-07171-3] [Reference Citation Analysis]
615 Shen YC, Lin ZZ, Hsu CH, Hsu C, Shao YY, Cheng AL. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2013;2:345-64. [PMID: 24400222 DOI: 10.1159/000343850] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
616 Marinelli S, Granito A, Piscaglia F, Renzulli M, Stagni A, Bolondi L. Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. Hepat Mon 2013;13:e11721. [PMID: 24282421 DOI: 10.5812/hepatmon.11721] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
617 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
618 Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol 2017;8:314-23. [PMID: 28480070 DOI: 10.21037/jgo.2016.09.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
619 Peungjesada S, Chuang HH, Prasad SR, Choi H, Loyer EM, Bronstein Y. Evaluation of cancer treatment in the abdomen: Trends and advances. World J Radiol 2013;5:126-42. [PMID: 23671749 DOI: 10.4329/wjr.v5.i3.126] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
620 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
621 Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett 2017;14:1637-47. [PMID: 28789390 DOI: 10.3892/ol.2017.6287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
622 Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ. Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol 2014;5:259-64. [PMID: 25083298 DOI: 10.3978/j.issn.2078-6891.2014.036] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
623 Abbattista MR, Jamieson SM, Gu Y, Nickel JE, Pullen SM, Patterson AV, Wilson WR, Guise CP. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biol Ther 2015;16:610-22. [PMID: 25869917 DOI: 10.1080/15384047.2015.1017171] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
624 Hong WF, Gu YJ, Wang N, Xia J, Zhou HY, Zhan K, Cheng MX, Cai Y. Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:301-14. [PMID: 34221916 DOI: 10.14218/JCTH.2020.00132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
625 Gbolahan OB, Schacht MA, Beckley EW, LaRoche TP, O'Neil BH, Pyko M. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8:215-228. [PMID: 28480062 DOI: 10.21037/jgo.2017.03.13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
626 Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol. 2019;25:2365-2372. [PMID: 31148907 DOI: 10.3748/wjg.v25.i19.2365] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
627 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget 2016;7:64400-9. [PMID: 27462865 DOI: 10.18632/oncotarget.10794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
628 Combs SE, Habermehl D, Ganten T, Schmidt J, Edler L, Burkholder I, Jäkel O, Haberer T, Debus J. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer. 2011;11:67. [PMID: 21314962 DOI: 10.1186/1471-2407-11-67] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
629 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
630 Kim HY, Kim CW. Ribonucleotide reductase subunit M2 can be new molecular target and prognostic biomarker of hepatocellular carcinoma. Gut Liver 2014;8:580-1. [PMID: 25368743 DOI: 10.5009/gnl14377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
631 Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond sorafenib. Curr Oncol Rep. 2012;14:257-266. [PMID: 22434314 DOI: 10.1007/s11912-11012-10233-11910] [Reference Citation Analysis]
632 Yoon HI, Song KJ, Lee IJ, Kim do Y, Han KH, Seong J. Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Cancer Res Treat. 2016;48:190-197. [PMID: 25761480 DOI: 10.4143/crt.2014.276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
633 Kong J, Zhang Q, Liang X, Sun W. FOXK2 downregulation suppresses EMT in hepatocellular carcinoma. Open Med (Wars) 2020;15:702-8. [PMID: 33313412 DOI: 10.1515/med-2020-0129] [Reference Citation Analysis]
634 Gadaleta-Caldarola G, Infusino S, Galise I, Ranieri G, Vinciarelli G, Fazio V, Divella R, Daniele A, Filippelli G, Gadaleta CD. Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study.Oncol Lett. 2014;8:1783-1787. [PMID: 25202410 DOI: 10.3892/ol.2014.2376] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
635 Tomimaru Y, Aihara A, Wands JR, Aloman C, Kim M. A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 Isoform. Transl Oncol 2019;12:1345-56. [PMID: 31352197 DOI: 10.1016/j.tranon.2019.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
636 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012;4:381-6. [PMID: 23181103 DOI: 10.3892/etm.2012.611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
637 Zheng M, Xu H, Liao XH, Chen CP, Zhang AL, Lu W, Wang L, Yang D, Wang J, Liu H, Zhou XZ, Lu KP. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma. Oncotarget 2017;8:29771-84. [PMID: 28404959 DOI: 10.18632/oncotarget.15967] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
638 Bae SH, Jang WI, Park HC. Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. Oncotarget. 2017;8:59965-59976. [PMID: 28938697 DOI: 10.18632/oncotarget.19219] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
639 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015;7:566-74. [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
640 Kong JY, Li SM, Fan HY, Zhang L, Zhao HJ, Li SM. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872. [PMID: 30113483 DOI: 10.1097/MD.0000000000011872] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
641 Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
642 Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis. 2013;4:e485. [PMID: 23392173 DOI: 10.1038/cddis.2013.18] [Cited by in Crossref: 120] [Cited by in F6Publishing: 124] [Article Influence: 15.0] [Reference Citation Analysis]
643 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
644 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. Liver Cancer 2017;6:227-35. [PMID: 28626733 DOI: 10.1159/000475777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
645 Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J, Tse G, Zhong L. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett 2021;21:315. [PMID: 33692847 DOI: 10.3892/ol.2021.12576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
646 Li Y, Lu J, Chen Q, Han S, Shao H, Chen P, Jin Q, Yang M, Shangguan F, Fei M, Wang L, Liu Y, Liu N, Lu B. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling. Arch Toxicol 2019;93:3367-83. [PMID: 31563988 DOI: 10.1007/s00204-019-02579-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
647 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
648 Gupta M, Iyer RV. Hepatocellular Carcinoma: Special Issue Highlights. Cancers (Basel) 2020;12:E2026. [PMID: 32722037 DOI: 10.3390/cancers12082026] [Reference Citation Analysis]
649 Rodríguez-Hernández A, Navarro-Villarán E, González R, Pereira S, Soriano-De Castro LB, Sarrias-Giménez A, Barrera-Pulido L, Álamo-Martínez JM, Serrablo-Requejo A, Blanco-Fernández G, Nogales-Muñoz A, Gila-Bohórquez A, Pacheco D, Torres-Nieto MA, Serrano-Díaz-Canedo J, Suárez-Artacho G, Bernal-Bellido C, Marín-Gómez LM, Barcena JA, Gómez-Bravo MA, Padilla CA, Padillo FJ, Muntané J. Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells. Redox Biol 2015;6:174-82. [PMID: 26233703 DOI: 10.1016/j.redox.2015.07.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
650 Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol 2017;9:615-26. [PMID: 28974984 DOI: 10.1177/1758834017728018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
651 Li JQ, Wu X, Gan L, Yang XL, Miao ZH. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells. Acta Pharmacol Sin 2017;38:1642-54. [PMID: 28713155 DOI: 10.1038/aps.2017.79] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
652 Wang W, Guo Y, Zhong J, Wang Q, Wang X, Wei H, Li J, Xiu P. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep 2021;11:2415. [PMID: 33510294 DOI: 10.1038/s41598-021-82058-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
653 Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010;9:956-70. [PMID: 21119733 DOI: 10.1038/nrd3297] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 9.6] [Reference Citation Analysis]
654 Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13:60. [PMID: 23566041 DOI: 10.1186/1471-230x-13-60] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
655 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
656 Liu KC, Hao YH, Lv WF, Jia WD, Ji CS, Zhou CZ, Cheng DL, Xu SB, Gao ZG, Su MX, Shi CS. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:3461-8. [PMID: 32904650 DOI: 10.2147/DDDT.S248850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
657 Zhou TY, Zhuang LH, Hu Y, Zhou YL, Lin WK, Wang DD, Wan ZQ, Chang LL, Chen Y, Ying MD, Chen ZB, Ye S, Lou JS, He QJ, Zhu H, Yang B. Inactivation of hy